Tag: HER2Overexpressing

Articles

• Breast cancer in Asian Americans
• Breast cancer types
• Ductal carcinoma in situ (DCIS) prognosis
• Exercise and breast cancer survival
• Family history means higher risk and getting cancer at a younger age
• Foods to eat and avoid during treatment with Herceptin
• Foods to eat and avoid for HER2+ patients and survivors
• HER2+ breast cancer characteristics
• HER2+ recurrence & survival data
• Hormone receptor and HER2 status changes can influence prognosis
• Obesity increases risk of breast cancer and worsens prognosis

News

08/06/24

Apple flavonoid phloretin enhances anti-cancer effects of Herceptin

10/07/20

Differences in HER2 expression between tumors affects outcomes

09/10/19

Watercress compound PEITC inhibits progression of HER2+ BC

03/11/18

Flaxseed lignans increase treatment effects of Adriamycin & Taxotere

05/01/16

Six-month delay in starting Herceptin linked to reduced survival

08/22/15

Dietary sugar promotes breast cancer development and metastasis

05/23/15

Sulforaphane inhibits HER2+ and triple negative breast cancer

07/20/14

HER2 status of lymph nodes can differ from that of primary tumor

10/31/13

Poor glucose control could reduce metformin's anti-cancer benefits

05/31/13

Black pepper compound increases effectiveness of Taxol in HER2+ BC

04/28/13

High circulating insulin increases HER2+ tumor size and metastases

01/20/13

Some BC types have up to 11% locoregional recurrence after mastectomy

12/27/12

Fish oil inhibits early stages of HER2+ tumor development

07/22/12

Inflammation can contribute to resistance to Herceptin

05/13/12

A story of long-term stage IV HER2+ breast cancer survival

04/19/12

Green tea polyphenol EGCG slows development of tamoxifen resistance

04/12/12

Five-year prognosis by breast cancer subtype

01/18/12

High intake of soy isoflavones increases risk of HER2+ recurrence

01/17/12

Apigenin increases effectiveness of Taxol chemotherapy

12/13/11

Metformin improves survival of diabetic women with HER2+ BC

12/02/11

Knowing receptor status of metastases improves treatment decisions

12/01/11

Herceptin + anthracycline chemo increases risk of cardiomyopathy

10/22/11

Young breast cancer patients require aggressive treatment

10/20/11

Age and breast cancer subtype influence prognosis after lumpectomy

08/01/11

BC subtype influences prognosis after neoadjuvant chemotherapy

05/09/11

Curcumin and DHA act synergistically in ER-/PR-/HER2+ breast cancer

03/30/11

Although similar, ER+/PR- BC is more aggressive than ER+/PR+

03/02/11

Risk of second primary breast cancer highest in ER-/PR- survivors

12/17/10

Cigarette smoking reduces breast cancer survival

10/23/10

Asian-American women have higher rates of HER2+ breast cancer

09/14/10

Does a family history of BC increase the risk of certain subtypes?

07/17/10

Oleic acid promotes breast cancer cell invasiveness

01/05/10

Pomegranate compounds inhibit aromatase and reduces proliferation

Studies

• Survival outcomes for HER2-low breast cancer: Danish national data Cite
  Sode M, Nielsen K, Jensen M, Berg T, Knoop A, Ejlertsen B, et al. Survival outcomes for HER2-low breast cancer: Danish national data. Acta Oncologica. MJS Publishing, Medical Journals Sweden AB; 2024; 63:878-886 10.2340/1651-226x.2024.41280
• Recent Developments in Luteolin-Loaded Nanoformulations for Enhanced Anti-Carcinogenic Activities: Insights from In Vitro and In Vivo Studies Cite
  Mod Razif MRF, Chan SY, Chew Y, Hassan M, Ahmad Hisham S, Abdul Rahman S, et al. Recent Developments in Luteolin-Loaded Nanoformulations for Enhanced Anti-Carcinogenic Activities: Insights from In Vitro and In Vivo Studies. Sci. MDPI AG; 2024; 6:68 10.3390/sci6040068
• Characterization of Molecular Subtypes of Rat Mammary Cancer and Their Association With Environmental Exposures Cite
  NISHIMURA Y, IIZUKA D, TAKABATAKE M, DAINO K, NISHIMURA M, MORIOKA T, et al. Characterization of Molecular Subtypes of Rat Mammary Cancer and Their Association With Environmental Exposures. Anticancer Research. Anticancer Research USA Inc.; 2024; 44:4261-4272 10.21873/anticanres.17256
• Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+ breast cancer cells Cite
  Tut E, Guldu OK, Medine EI. Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+ breast cancer cells. Journal of Drug Delivery Science and Technology. Elsevier BV; 2024; 101:106243 10.1016/j.jddst.2024.106243
• Abstract C144: Poor survival in non-Hispanic Black HR+/HER2- and HR-/HER2+ breast cancer patients at an NCI-Designated Comprehensive Cancer Center Cite
  Lantz AE, Li J, Gebert RF, Chen D, Gordián ER, Cress WD. Abstract C144: Poor survival in non-Hispanic Black HR+/HER2- and HR-/HER2+ breast cancer patients at an NCI-Designated Comprehensive Cancer Center. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2024; 33:C144-C144 10.1158/1538-7755.disp24-c144
• Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis Cite
  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.23.02311
• HER2 status results in an unstable switch from primary to recurrent breast cancer Cite
  Zhu A, Wang N, Yun Z, Liu X, Liang X, Yan Y, et al. HER2 status results in an unstable switch from primary to recurrent breast cancer. Neoplasma. AEPress, s.r.o.; 2024; 71:392-401 10.4149/neo_2024_240229n89
• Racial/ethnic differences in the clinical presentation and survival of breast cancer by subtype Cite
  Nhim V, Bencomo-Alvarez AE, Alvarado L, Kilcoyne M, Gonzalez-Henry MA, Olivas IM, et al. Racial/ethnic differences in the clinical presentation and survival of breast cancer by subtype. Frontiers in Oncology. Frontiers Media SA; 2024; 14 10.3389/fonc.2024.1443399
• The Antitumour Mechanisms of Carotenoids: A Comprehensive Review Cite
  Baeza-Morales A, Medina-García M, Martínez-Peinado P, Pascual-García S, Pujalte-Satorre C, López-Jaén AB, et al. The Antitumour Mechanisms of Carotenoids: A Comprehensive Review. Antioxidants. MDPI AG; 2024; 13:1060 10.3390/antiox13091060
• Apoptotic effect of melatonin on ER-positive breast cancer cell lines: ADGRL4 gene expression and promoter methylation Cite
  Rajabi A, Safaralizadeh R, Saber A, Pourmahdi M, Teimourian S, Montazeri V, et al. Apoptotic effect of melatonin on ER-positive breast cancer cell lines: ADGRL4 gene expression and promoter methylation. Naunyn-Schmiedeberg's Archives of Pharmacology. Springer Science and Business Media LLC; 2024; 10.1007/s00210-024-03383-2
• Copper metabolism–related signature for Prognosis Prediction and MMP13 served as malignant factor for breast cancer Cite
  Han C, Feng Z, Wang Y, Hu M, Xu S, Jiang F, et al. Copper metabolism–related signature for Prognosis Prediction and MMP13 served as malignant factor for breast cancer. Heliyon. Elsevier BV; 2024;:e36445 10.1016/j.heliyon.2024.e36445
• Anticancer potential of delphinidin and its derivatives: therapeutic and mechanistic insights Cite
  Iqbal S, Omara T, Kahwa I, Khan UM. Anticancer potential of delphinidin and its derivatives: therapeutic and mechanistic insights. Medicinal Chemistry Research. Springer Science and Business Media LLC; 2024; 10.1007/s00044-024-03296-y
• Zinc transporter ZnT5 is associated with epithelial mesenchymal transition via SMAD1 in breast cancer Cite
  Iwabuchi E, Miki Y, Xu J, Kanai A, Ishida T, Sasano H, et al. Zinc transporter ZnT5 is associated with epithelial mesenchymal transition via SMAD1 in breast cancer. International Journal of Experimental Pathology. Wiley; 2024; 10.1111/iep.12515
• Crocin Induces Apoptosis in Primary Cancer Epithelial Cells Isolated from Human Breast Tumors via Different Mechanisms in HER2- Negative or Positive Cells: A Preliminary Study Cite
  Bathaie SZ, Faridi N, Hydrazideh H, Hashemi SA, Abroun S, Tamanoi F, et al. Crocin Induces Apoptosis in Primary Cancer Epithelial Cells Isolated from Human Breast Tumors via Different Mechanisms in HER2- Negative or Positive Cells: A Preliminary Study. Springer Science and Business Media LLC; 2024; 10.21203/rs.3.rs-4711052/v1
• Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease Cite
  Dowling GP, Keelan S, Cosgrove NS, Daly GR, Giblin K, Toomey S, et al. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07431-6
• Differential effects of docosahexaenoic acid (DHA) and linoleic acid (LA) on miR-101 and miR-342 tumor suppressor microRNAs in Taxol-treated HER2-positive breast cancer cells Cite
  Aslan C, Maralbashi S, Shekari N, Javadian M, Shomali N, Kazemi T. Differential effects of docosahexaenoic acid (DHA) and linoleic acid (LA) on miR-101 and miR-342 tumor suppressor microRNAs in Taxol-treated HER2-positive breast cancer cells. Clinical Nutrition ESPEN. Elsevier BV; 2024; 63:502-507 10.1016/j.clnesp.2024.07.007
• Apple polyphenol phloretin inhibits type II glucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer Cite
  Chang H, Cheng T, Tu S, Liao P, Lee Y, Ho C, et al. Apple polyphenol phloretin inhibits type II glucose transporter and enhances anti-HER2 antibody drug binding as an adjuvant treatment for HER2-positive breast cancer. Food Science and Human Wellness. Tsinghua University Press; 2024; 10.26599/fshw.2024.9250251
• Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial Cite
  Kettana KM, El‑Haggar SM, Alm El-Din MA, El‑Afify DR. Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Medical Oncology. Springer Science and Business Media LLC; 2024; 41 10.1007/s12032-024-02426-1
• A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression Cite
  Boman C, Liu X, Eriksson Bergman L, Sun W, Tranchell C, Toli MA, et al. A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression. British Journal of Cancer. Springer Science and Business Media LLC; 2024; 10.1038/s41416-024-02777-6
• Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer Cite
  Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi MA, et al. Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.23.01959
• Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study Cite
  John EM, Koo J, Phipps AI, Longacre TA, Kurian AW, Ingles SA, et al. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01834-5
• Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression Cite
  Franceschi BT, Bezerra PHA, Torqueti MR. Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01590-6
• An analysis of the association between breast density and body mass index with breast cancer molecular subtypes in early breast cancer: data from a Spanish population Cite
  Calvo I, González-Rodríguez M, Neria F, Gallegos I, García-Sánchez L, Sánchez-Gómez R, et al. An analysis of the association between breast density and body mass index with breast cancer molecular subtypes in early breast cancer: data from a Spanish population. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2024; 10.1007/s12094-024-03469-6
• Comparison of the Pathological Complete Response Rate and Survival between HER2-low and HER2-zero Breast Cancer in Neoadjuvant Chemotherapy Setting: a Systematic Review and Meta-analysis Cite
  Liu M, Xiang Q, Dai F, Yuan Y, Wu Z, Xiang T. Comparison of the Pathological Complete Response Rate and Survival between HER2-low and HER2-zero Breast Cancer in Neoadjuvant Chemotherapy Setting: a Systematic Review and Meta-analysis. Clinical Breast Cancer. Elsevier BV; 2024; 10.1016/j.clbc.2024.05.001
• Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer Cite
  Kutlu Y, Cekin R, Aydin SG, Shbair ATM, Bilici A, Arici S, et al. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer. Current Problems in Cancer. Elsevier BV; 2024; 50:101102 10.1016/j.currproblcancer.2024.101102
• Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer Cite
  Chen W, Zhang J, Li F, Chen Z, Li J, Lu D. Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2024; 22 10.1186/s12957-024-03366-w
• Discordance of HER2-low Status between Breast Primary and Distant Metastases with Clinical-pathological Correlation Cite
  Yang E, D’Alfonso T, Morrow M, Brogi E, Wen H. Discordance of HER2-low Status between Breast Primary and Distant Metastases with Clinical-pathological Correlation. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4284023/v1
• Abstract PO4-18-03: Combined Treatment with Pyrotinib and Chrysin Synergistically Improve the Autophagy Level in HER2-Positive Breast Cancer by Regulating the miR-16-5p/ZBTB16/G6PD Axis Cite
  Luo T, Zhong X, He P, Zheng D, Cheng Y, Zhu K. Abstract PO4-18-03: Combined Treatment with Pyrotinib and Chrysin Synergistically Improve the Autophagy Level in HER2-Positive Breast Cancer by Regulating the miR-16-5p/ZBTB16/G6PD Axis. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO4-18-03-PO4-18-03 10.1158/1538-7445.sabcs23-po4-18-03
• Treatment and survival of patients diagnosed with high-risk HR+/HER2− breast cancer in the Netherlands: a population-based retrospective cohort study Cite
  Lammers S, Meegdes M, Vriens I, Voogd A, de Munck L, van Nijnatten T, et al. Treatment and survival of patients diagnosed with high-risk HR+/HER2− breast cancer in the Netherlands: a population-based retrospective cohort study. ESMO Open. Elsevier BV; 2024; 9:103008 10.1016/j.esmoop.2024.103008
• Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status Cite
  Na S, Kim M, Park Y, Kwon HJ, Shin H, Kim E, et al. Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01585-3
• Exploring Anticancer Properties of Medicinal Plants against Breast Cancer by Downregulating Human Epidermal Growth Factor Receptor 2 Cite
  Gupta S, Prem R, Sethy C, Shrivastava S, Singh M, Yadav P, et al. Exploring Anticancer Properties of Medicinal Plants against Breast Cancer by Downregulating Human Epidermal Growth Factor Receptor 2. Journal of Agricultural and Food Chemistry. American Chemical Society (ACS); 2024; 10.1021/acs.jafc.3c07565
• Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Cite
  Masuda Y, Yamashita S, Nakayama Y, Shimizu R, Konishi M. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Biological and Pharmaceutical Bulletin. Pharmaceutical Society of Japan; 2024; 47:840-847 10.1248/bpb.b23-00802
• HER2 Low Expression in Primary Male Breast Cancer Cite
  Nobbe K, Erices-Leclercq M, Foerster F, Förster R, Baldus S, Rudlowski C, et al. HER2 Low Expression in Primary Male Breast Cancer. Breast Cancer: Targets and Therapy. Informa UK Limited; 2024; Volume 16:141-148 10.2147/bctt.s450682
• Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study Cite
  Acs B, Hartman J, Sönmez D, Lindman H, Johansson AL, Fredriksson I. Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study. The Lancet Regional Health - Europe. Elsevier BV; 2024;:100886 10.1016/j.lanepe.2024.100886
• The eugenol functionalized B12N12 and B16N16 cages as potential inhibitors of TNF-α and HER2 receptors Cite
  Mejía N, Katherine Campoverde Santos D, Andrés Mancheno Herrera C, Kumar A, Kaur H, Nadhim Shaker R, et al. The eugenol functionalized B12N12 and B16N16 cages as potential inhibitors of TNF-α and HER2 receptors. Polyhedron. Elsevier BV; 2024;:116935 10.1016/j.poly.2024.116935
• Molecular and clinical portrait of HER2-low invasive lobular carcinomas Cite
  Djerroudi L, El Sabeh-Ayoun A, Benoist C, Pierron G, Masliah-Planchon J, Fuhrmann L, et al. Molecular and clinical portrait of HER2-low invasive lobular carcinomas. Modern Pathology. Elsevier BV; 2024;:100463 10.1016/j.modpat.2024.100463
• Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer Cite
  Yılmaz M, Erdiş E, Uçar M, Demir N, Alandağ C, Yücel B. Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2024; 10.1093/jjco/hyae010
• Long-term cadmium exposure induces epithelial-mesenchymal transition in breast cancer cells by activating CYP1B1-mediated glutamine metabolic reprogramming in BT474 cells and MMTV-Erbb2 mice Cite
  Li J, Gao P, Qin M, Wang J, Luo Y, Deng P, et al. Long-term cadmium exposure induces epithelial-mesenchymal transition in breast cancer cells by activating CYP1B1-mediated glutamine metabolic reprogramming in BT474 cells and MMTV-Erbb2 mice. Science of The Total Environment. Elsevier BV; 2024; 918:170773 10.1016/j.scitotenv.2024.170773
• Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab Cite
  Zhou S, Cirne F, Chow J, Zereshkian A, Bordeleau L, Dhesy-Thind S, et al. Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab. The Oncologist. Oxford University Press (OUP); 2023; 28:e712-e722 10.1093/oncolo/oyad086
• Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer Cite
  Wei T, Kang Y, Wang X, Yue J, Xu B, Yuan P. Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer. Thoracic Cancer. Wiley; 2024; 10.1111/1759-7714.15221
• The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes Cite
  Ngô TM, Lê ÁN, Đinh DPH. The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes. Current Oncology. MDPI AG; 2024; 31:649-659 10.3390/curroncol31020047
• Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes Cite
  Ding W, Ye D, Chen H, Lin Y, Li Z, Tu C. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-023-01538-2
• High linoleic acid levels in red blood cells predict a poor response to neoadjuvant chemotherapy in HER2-positive breast cancer patients Cite
  Valenzuela R, Walbaum B, Farias C, Acevedo F, Vargas C, Bennett JT, et al. High linoleic acid levels in red blood cells predict a poor response to neoadjuvant chemotherapy in HER2-positive breast cancer patients. Nutrition. Elsevier BV; 2024;:112357 10.1016/j.nut.2024.112357
• Association between trans fatty acids and Subtypes of breast cancer: A Mendelian randomization study Cite
  liu X, Zhang S, Fang X. Association between trans fatty acids and Subtypes of breast cancer: A Mendelian randomization study. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-3841251/v1
• Anthocyanin Oligomers Induce Apoptosis and Autophagy by Inhibiting the mTOR Signaling Pathway in Human Breast Cancer Cells Cite
  Lee M, Hong H, Nam K. Anthocyanin Oligomers Induce Apoptosis and Autophagy by Inhibiting the mTOR Signaling Pathway in Human Breast Cancer Cells. Pharmaceuticals. MDPI AG; 2023; 17:24 10.3390/ph17010024
• Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations Cite
  Akkoc Mustafayev FN, Shukla MA, Lanier A, Milton DR, Gutierrez AM, Gruschkus SK, et al. Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations. Cancer. Wiley; 2023; 10.1002/cncr.35159
• Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer Cite
  González-Rodríguez M, Ait Edjoudi D, Cordero-Barreal A, Farrag M, Varela-García M, Torrijos-Pulpón C, et al. Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer. Antioxidants. MDPI AG; 2023; 12:2112 10.3390/antiox12122112
• Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study Cite
  Hung S, Yang H, Lee M, Liu D, Chen L, Chew C, et al. Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01747-9
• Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer Cite
  Roy AM, Patel A, Catalfamo K, Attwood K, Khoury T, Yao S, et al. Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2023; 6:e2344517 10.1001/jamanetworkopen.2023.44517
• Synergistic Anti-Cancer Potential of Phenethyl Isothiocyanate and Curcumin Induces Apoptosis and G2/M Cell Cycle Arrest in HER2-Positive Breast Cancer Cells Cite
  Sirigiripeta S, Dokala A, Anupalli R. Synergistic Anti-Cancer Potential of Phenethyl Isothiocyanate and Curcumin Induces Apoptosis and G2/M Cell Cycle Arrest in HER2-Positive Breast Cancer Cells. Cytology and Genetics. Allerton Press; 2023; 57:611-624 10.3103/s0095452723060087
• First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Cite
  Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, et al. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. European Journal of Cancer. Elsevier BV; 2024; 196:113422 10.1016/j.ejca.2023.113422
• Exposure to outdoor artificial light at night and breast cancer risk: a population-based case-control study in two French departments (the CECILE study) Cite
  Prajapati N, Cordina-Duverger E, Boileau A, Faure E, Guénel P. Exposure to outdoor artificial light at night and breast cancer risk: a population-based case-control study in two French departments (the CECILE study). Frontiers in Environmental Health. Frontiers Media SA; 2023; 2 10.3389/fenvh.2023.1268828
• SAT428 The Effects Of Diphenyl Phthalate (DP) On Estrogen Receptor Alpha (ERα;) And Tumor Suppressor Gene (BRCA-1) In Breast Cancer Cells Cite
  Whittaker K, Hallman E, Zanib A, Pfiffner S, Yaldo R, Dinda S. SAT428 The Effects Of Diphenyl Phthalate (DP) On Estrogen Receptor Alpha (ERα;) And Tumor Suppressor Gene (BRCA-1) In Breast Cancer Cells. Journal of the Endocrine Society. The Endocrine Society; 2023; 7 10.1210/jendso/bvad114.1059
• Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis Cite
  PETRELLI F, REA C, PARATI MC, BORGONOVO K, GHILARDI M, DOTTORINI L, et al. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis. Anticancer Research. Anticancer Research USA Inc.; 2023; 43:4303-4313 10.21873/anticanres.16625
• Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan Cite
  Haque R, Chen LH, Oestreicher N, Lalla D, Chlebowski RT. Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan. Breast Cancer: Targets and Therapy. Informa UK Limited; 2023; Volume 15:637-645 10.2147/bctt.s420061
• Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases Cite
  Zhu S, Lu Y, Fei X, Shen K, Chen X. Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-023-02403-x
• Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study Cite
  Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby SC, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study. BMJ. BMJ; 2023;:e074684 10.1136/bmj-2022-074684
• Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact Cite
  Schandiz H, Park D, Kaiser YL, Lyngra M, Talleraas IS, Geisler J, et al. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 201:329-338 10.1007/s10549-023-07016-9
• A Systematic Ex-Vivo Study of the Anti-Proliferative/Cytotoxic Bioactivity of Major Olive Secoiridoids’ Double Combinations and of Total Olive Oil Phenolic Extracts on Multiple Cell-Culture Based Cancer Models Highlights Synergistic Effects Cite
  Papakonstantinou A, Koumarianou P, Diamantakos P, Melliou E, Magiatis P, Boleti H. A Systematic Ex-Vivo Study of the Anti-Proliferative/Cytotoxic Bioactivity of Major Olive Secoiridoids’ Double Combinations and of Total Olive Oil Phenolic Extracts on Multiple Cell-Culture Based Cancer Models Highlights Synergistic Effects. Nutrients. MDPI AG; 2023; 15:2538 10.3390/nu15112538
• A comprehensive review of the health benefits of flaxseed oil in relation to its chemical composition and comparison with other omega-3-rich oils Cite
  Al-Madhagy S, Ashmawy NS, Mamdouh A, Eldahshan OA, Farag MA. A comprehensive review of the health benefits of flaxseed oil in relation to its chemical composition and comparison with other omega-3-rich oils. European Journal of Medical Research. Springer Science and Business Media LLC; 2023; 28 10.1186/s40001-023-01203-6
• The Combined Therapeutic Effect of Capecitabine and Naringin on HER2+ (SK-BR-3) and HER2- (MCF-7) Human Breast Cancer Cells Lines Cite
  Soltannezhad S, Jouni FJ, Osgoei LT. The Combined Therapeutic Effect of Capecitabine and Naringin on HER2+ (SK-BR-3) and HER2- (MCF-7) Human Breast Cancer Cells Lines. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2887641/v1
• The dynamics of HER2-low expression during breast cancer progression Cite
  Anderson S, Bartow BB, Siegal GP, Huang X, Wei S. The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07020-z
• Predictive biological factors for late survival in patients with HER2-positive breast cancer Cite
  Kang Y, Oh SJ, Bae SY, Kim E, Lee Y, Park EH, et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2023; 13 10.1038/s41598-023-38200-y
• Environmental cadmium exposure facilitates mammary tumorigenesis via reprogramming gut microbiota-mediated glutamine metabolism in MMTV-Erbb2 mice Cite
  Yue Y, Zhang H, Deng P, Tan M, Chen C, Tang B, et al. Environmental cadmium exposure facilitates mammary tumorigenesis via reprogramming gut microbiota-mediated glutamine metabolism in MMTV-Erbb2 mice. Science of The Total Environment. Elsevier BV; 2023;:165348 10.1016/j.scitotenv.2023.165348
• Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers Cite
  Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, et al. Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 129:122-134 10.1038/s41416-023-02287-x
• Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis Cite
  Ploumen RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, van Kats MACE, Gommers S, et al. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07012-z
• Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy Cite
  Tuluhong D, Li X, Gao H, Zhu Y, Li Q, Wang S. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2023; 32:377-387 10.1097/cej.0000000000000813
• Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study Cite
  Shi Y, Qiu Z, Yu J, Li Z, Hua S, Chen Y, et al. Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11102-y
• Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients Cite
  Miyamoto N, Inoue H, Inui T, Sasa S, Aoyama M, Okumura K, et al. Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2023; 23:e68-e76 10.1016/j.clbc.2023.01.005
• Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study Cite
  Hsieh H, Wu T, Chen C, Kuo Y, Hour M. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study. Therapeutic Advances in Drug Safety. SAGE Publications; 2023; 14 10.1177/20420986231181338
• Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis Cite
  Chen L, Wu F, Chen X, Chen Y, Deng L, Cai Q, et al. Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00552-z
• Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database Cite
  Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, et al. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncology. American Medical Association (AMA); 2023; 9:500 10.1001/jamaoncol.2022.7476
• An investigation into the effects of 6-Gingerol on glucose and glutamine metabolism in breast cancer cell lines Cite
  Ghorbani M, Shafiee SM, Dianati-Nassab A, Behbahani SE, Honardar Z, Khoshdel Z. An investigation into the effects of 6-Gingerol on glucose and glutamine metabolism in breast cancer cell lines. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2707034/v1
• Epstein-Barr virus in breast carcinoma and in triple negative cases impact on clinical outcomes Cite
  Mekrazi S, Kallel I, Jamai D, Yengui M, Khabir A, Gdoura R. Epstein-Barr virus in breast carcinoma and in triple negative cases impact on clinical outcomes. Pathology - Research and Practice. Elsevier BV; 2023; 245:154484 10.1016/j.prp.2023.154484
• Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications Cite
  Bashraheel SS, Kheraldine H, Khalaf S, Moustafa AA. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. Biomedicine & Pharmacotherapy. Elsevier BV; 2023; 162:114676 10.1016/j.biopha.2023.114676
• Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) Cite
  Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01626-3
• Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients Cite
  Bo J, Yu B, Bi R, Xu X, Cheng Y, Tu X, et al. Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2023; 10.1016/j.clbc.2023.03.002
• HER2-Low Breast Cancer: a New Subtype? Cite
  Corti C, Giugliano F, Nicolò E, Tarantino P, Criscitiello C, Curigliano G. HER2-Low Breast Cancer: a New Subtype?. Current Treatment Options in Oncology. Springer Science and Business Media LLC; 2023; 10.1007/s11864-023-01068-1
• Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy Cite
  Ma Y, Zhu M, Lv M, Yuan P, Chen X, Liu Z. Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy. Cancer Medicine. Wiley; 2023; 10.1002/cam4.5839
• Prognostic and Predictive Biomarkers in Familial Breast Cancer Cite
  Deb S, Chakrabarti A, Fox SB. Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers. MDPI AG; 2023; 15:1346 10.3390/cancers15041346
• Cognitive function and breast cancer molecular subtype before and after chemotherapy Cite
  Hsu Y, Chen H, Wu S, Tzang B, Hsieh C, Weng Y, et al. Cognitive function and breast cancer molecular subtype before and after chemotherapy. Applied Neuropsychology: Adult. Informa UK Limited; 2023;:1-8 10.1080/23279095.2023.2176233
• A real-world data retrospective cohort study of HER2-positive, early-stage breast cancer in patients 70 years of age or older: natural history, treatment patterns, and outcomes Cite
  Bari S, Li J, Kang D, Jameel Z, Czerniecki BJ, Costa RL. A real-world data retrospective cohort study of HER2-positive, early-stage breast cancer in patients 70 years of age or older: natural history, treatment patterns, and outcomes. Clinical Breast Cancer. Elsevier BV; 2023; 10.1016/j.clbc.2023.01.013
• HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study Cite
  kada Mohammed S, Billa O, Ladoire S, Jankowski C, Desmoulins I, Poillot M, et al. HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study. Breast Cancer. Springer Science and Business Media LLC; 2023; 10.1007/s12282-022-01432-3
• Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer Cite
  Almstedt K, Krauthauser L, Kappenberg F, Wagner D, Heimes A, Battista MJ, et al. Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2478913/v1
• The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups Cite
  Zheng H, Ge C, Lin H, Zhou S, Tang W, Wang Q, et al. The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups. PLOS ONE. Public Library of Science (PLoS); 2023; 18:e0280474 10.1371/journal.pone.0280474
• Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years Cite
  KIKUCHI M, FUJII T, HONDA C, TANABE K, NAKAZAWA Y, OGINO M, et al. Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years. Anticancer Research. Anticancer Research USA Inc.; 2022; 43:217-221 10.21873/anticanres.16152
• Characteristics, treatment and outcomes of HER2 positive male breast cancer Cite
  Esposito A, Ablah E, Okut H, Tenofsky PL. Characteristics, treatment and outcomes of HER2 positive male breast cancer. The American Journal of Surgery. Elsevier BV; 2022; 10.1016/j.amjsurg.2022.12.009
• Parabens preferentially accumulate in metastatic breast tumors compared to benign breast tumors and the association of breast cancer risk factors with paraben accumulation Cite
  Downs CA, Amin MM, Tabatabaeian M, Chavoshani A, Amjadi E, Afshari A, et al. Parabens preferentially accumulate in metastatic breast tumors compared to benign breast tumors and the association of breast cancer risk factors with paraben accumulation. Environmental Advances. Elsevier BV; 2022;:100325 10.1016/j.envadv.2022.100325
• Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study Cite
  Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, et al. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. Springer Science and Business Media LLC; 2022; 127:1799-1807 10.1038/s41416-022-01963-8
• Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls Cite
  Morganti S, Ivanova M, Ferraro E, Ascione L, Vivanet G, Bonizzi G, et al. Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. Cancer Drug Resistance. OAE Publishing Inc.; 2022; 5:971-80 10.20517/cdr.2022.55
• Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden Cite
  Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden. BMC Cancer. Springer Science and Business Media LLC; 2022; 22 10.1186/s12885-022-10098-1
• Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy Cite
  Kang S, Lee SH, Lee HJ, Jeong H, Jeong JH, Kim JE, et al. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. European Journal of Cancer. Elsevier BV; 2022; 176:30-40 10.1016/j.ejca.2022.08.031
• Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study Cite
  Liikanen JS, Leidenius M, Joensuu H, Meretoja TJ. Long-Term Survival Outcomes of Patients with Small (≤1 cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study. Breast Care. S. Karger AG; 2022; 17:279-287 10.1159/000520793
• Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study Cite
  Ihenacho U, Hamilton AS, Mack WJ, Wu AH, Unger JB, Pathak DR, et al. Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06675-4
• Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer Cite
  Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, et al. Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. The Breast. Elsevier BV; 2022; 65:145-150 10.1016/j.breast.2022.07.012
• The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine Cite
  Di Modica M, Arlotta V, Sfondrini L, Tagliabue E, Triulzi T. The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine. Frontiers in Oncology. Frontiers Media SA; 2022; 12 10.3389/fonc.2022.947188
• Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis Cite
  Tomasello G, Gambini D, Petrelli F, Azzollini J, Arcanà C, Ghidini M, et al. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. ESMO Open. Elsevier BV; 2022; 7:100531 10.1016/j.esmoop.2022.100531
• Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer. Cite
  Barakat D, Mohamed R, Elnaggar M, Tarik D, Eid SM. Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:552-552 10.1200/jco.2022.40.16_suppl.552
• An appropriate treatment interval does not affect the prognosis of patients with breast Cancer Cite
  Gao W, Wang J, Yin S, Geng C, Xu B. An appropriate treatment interval does not affect the prognosis of patients with breast Cancer. Holistic Integrative Oncology. Springer Science and Business Media LLC; 2022; 1 10.1007/s44178-022-00010-z
• The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute Cite
  Gamrani S, Boukansa S, Benbrahim Z, Mellas N, Fdili Alaoui F, Melhouf MA, et al. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute. The Breast Journal. Hindawi Limited; 2022; 2022:1-9 10.1155/2022/9238804
• Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection Cite
  Shirmard LR, Shabani M, Moghadam AA, Zamani N, Ghanbari H, Salimi A. Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection. Cardiovascular Toxicology. Springer Science and Business Media LLC; 2022; 10.1007/s12012-022-09750-w
• Investigation of HER-3 gene expression under the influence of carbohydrate biopolymers extract of shiitake and reishi in MCF-7 cell line Cite
  Larypoor M. Investigation of HER-3 gene expression under the influence of carbohydrate biopolymers extract of shiitake and reishi in MCF-7 cell line. Molecular Biology Reports. Springer Science and Business Media LLC; 2022; 10.1007/s11033-022-07496-w
• Ambient air emissions of endocrine-disrupting metals and the incidence of hormone receptor- and HER2-dependent female breast cancer in USA Cite
  Ro E, Vu V, Wei Y. Ambient air emissions of endocrine-disrupting metals and the incidence of hormone receptor- and HER2-dependent female breast cancer in USA. Medical Oncology. Springer Science and Business Media LLC; 2022; 39 10.1007/s12032-022-01667-2
• Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study Cite
  Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.01736
• Abstract P3-18-03: Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC) Cite
  Wang K, Duinmeijer A, Matikas A, Altena R, Johansson H, Fredholm H, et al. Abstract P3-18-03: Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC). Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-18-03-P3-18-03 10.1158/1538-7445.sabcs21-p3-18-03
• Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy Cite
  Yang L, Shen M, Qiu Y, Tingting T, Bu H. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. The Breast. Elsevier BV; 2022; 10.1016/j.breast.2022.03.019
• Omega-9 fatty acids: potential roles in inflammation and cancer management Cite
  Farag MA, Gad MZ. Omega-9 fatty acids: potential roles in inflammation and cancer management. Journal of Genetic Engineering and Biotechnology. Springer Science and Business Media LLC; 2022; 20 10.1186/s43141-022-00329-0
• Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society Cite
  Won HS, Ahn J, Kim Y, Kim JS, Song J, Kim H, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Research. Springer Science and Business Media LLC; 2022; 24 10.1186/s13058-022-01519-x
• Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells Cite
  Han S, Lee J, Woo J, Jung G, Jung S, Han E, et al. Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells. International Journal of Molecular Medicine. Spandidos Publications; 2022; 49 10.3892/ijmm.2022.5110
• Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics Cite
  Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0264637 10.1371/journal.pone.0264637
• Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer Cite
  Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, et al. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer. Cancers. MDPI AG; 2022; 14:1015 10.3390/cancers14041015
• Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience Cite
  Okines A, Irfan T, Asare B, Mohammed K, Osin P, Nerurkar A, et al. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06432-z
• Minireview: Parabens Exposure and Breast Cancer Cite
  Hager E, Chen J, Zhao L. Minireview: Parabens Exposure and Breast Cancer. International Journal of Environmental Research and Public Health. MDPI AG; 2022; 19:1873 10.3390/ijerph19031873
• The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry Cite
  Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, et al. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06472-5
• The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study Cite
  Han Y, Wu Y, Xu H, Wang J, Xu B. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. International Journal of Clinical Oncology. Springer Science and Business Media LLC; 2022; 10.1007/s10147-022-02115-x
• The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study Cite
  Patel R, Lyne-Ethier J, Brogly S, Griffiths R, Hendry JM. The effect of trastuzumab on taxane-induced peripheral neuropathy in women with breast cancer: a population-based cohort study. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1254626/v1
• Predictive and prognostic significance of BRCAness in HER2-negative breast cancer Cite
  Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, et al. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2022; 10.1007/s12282-021-01319-9
• Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer Cite
  Yao N, Shi W, Liu T, Siyin ST, Wang W, Duan N, et al. Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-021-04342-0
• Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients Cite
  Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet Oncology. Elsevier BV; 2021; 10.1016/s1470-2045(21)00589-1
• In silico study of lutein as anti-HER-2 receptors in breast cancer treatment Cite
  Cahyani NKN, Putri WNE, Dwivayana IKD, Mirayanti NPD, Laksmiani NPL. In silico study of lutein as anti-HER-2 receptors in breast cancer treatment. Pharmacy Reports. Indonesian Young Scientist Group; 2021; 1:17 10.51511/pr.17
• The effects of vitamin D (Vit D) replacement on pathological complete response (PCR) in breast cancer (BC) patients receiving neoadjuvant systemic chemotherapy (NAC). Cite
  Ozmen V, Ordu C, Ilgun AS, Unal C, Soybir G, Erdogan Z, et al. The effects of vitamin D (Vit D) replacement on pathological complete response (PCR) in breast cancer (BC) patients receiving neoadjuvant systemic chemotherapy (NAC).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021; 39:e12604-e12604 10.1200/jco.2021.39.15_suppl.e12604
• Disease characteristics and mortality among Asian women with breast cancer Cite
  Yu AYL, Thomas SM, DiLalla GD, Greenup RA, Hwang ES, Hyslop T, et al. Disease characteristics and mortality among Asian women with breast cancer. Cancer. Wiley; 2021; 10.1002/cncr.34015
• A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer Cite
  Subramaniyan V, Fuloria S, Gupta G, Kumar DH, Sekar M, Sathasivam KV, et al. A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer. Chemico-Biological Interactions. Elsevier BV; 2022; 351:109735 10.1016/j.cbi.2021.109735
• New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects Cite
  Arena A, Romeo MA, Benedetti R, Masuelli L, Bei R, Gilardini Montani MS, et al. New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects. Pharmaceuticals. MDPI AG; 2021; 14:1068 10.3390/ph14111068
• HER2-low breast cancer could be associated with an increased risk of brain metastasis Cite
  Guven DC, Kaya MB, Fedai B, Ozden M, Yildirim HC, Kosemehmetoglu K, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. International Journal of Clinical Oncology. Springer Science and Business Media LLC; 2021; 10.1007/s10147-021-02049-w
• Evolution of HER2-low expression from primary to recurrent breast cancer Cite
  Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00343-4
• A careful reassessment of anthracycline use in curable breast cancer Cite
  Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, et al. A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00342-5
• Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years Cite
  Riyad AY, Elkhodary DA, Elghamry WRF, Zaki IAKM. Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years. QJM: An International Journal of Medicine. Oxford University Press (OUP); 2021; 114 10.1093/qjmed/hcab103.010
• Reproductive history differs by molecular subtypes of breast cancer among women aged ≤50 years in Scotland in 2009-16: A population-based retrospective cohort study Cite
  Chitkara A, Mesa-Eguiagaray I, Wild SH, Hall PS, Cameron D, Figueroa J. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤50 years in Scotland in 2009-16: A population-based retrospective cohort study. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-940729/v1
• Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database Cite
  Annonay M, Gauquelin L, Geiss R, Ung M, Cristol-Dalstein L, Mouret-Reynier M, et al. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. The Breast. Elsevier BV; 2021; 60:138-146 10.1016/j.breast.2021.09.011
• Delphinidin induces cell cycle arrest and apoptosis in HER‑2 positive breast cancer cell lines by regulating the NF‑κB and MAPK signaling pathways Cite
  Wu A, Zhu Y, Han B, Peng J, Deng X, Chen W, et al. Delphinidin induces cell cycle arrest and apoptosis in HER‑2 positive breast cancer cell lines by regulating the NF‑κB and MAPK signaling pathways. Oncology Letters. Spandidos Publications; 2021; 22 10.3892/ol.2021.13093
• Health-promoting effects of bioactive compounds in blackcurrant (Ribes nigrum L.) Berries Cite
  Oczkowski M. Health-promoting effects of bioactive compounds in blackcurrant (Ribes nigrum L.) Berries. Roczniki Państwowego Zakładu Higieny. National Institute of Public Health – National Institute of Hygiene; 2021;:229-238 10.32394/rpzh.2021.0174
• 188P Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: A double blind, randomized clinical trial Cite
  Javadinia S, Salek R, Dehghani M, Mohajeri S, Talaei A, Fanipakdel A. 188P Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: A double blind, randomized clinical trial. Annals of Oncology. Elsevier BV; 2021; 32:S439-S440 10.1016/j.annonc.2021.08.469
• Luteolin-Loading Her-2 Nanospheres Enhances Targeting and Therapeutic Effects of Breast Cancer Cite
  Xiao C, Wang X, Shen J, Xia Y, Qiu S, Liang X, et al. Luteolin-Loading Her-2 Nanospheres Enhances Targeting and Therapeutic Effects of Breast Cancer. Journal of Biomedical Nanotechnology. American Scientific Publishers; 2021; 17:1545-1553 10.1166/jbn.2021.3137
• Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1 Cite
  Woo J, Kim JB, Cho T, Yoo EH, Moon B, Kwon H, et al. Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1. PLOS ONE. Public Library of Science (PLoS); 2021; 16:e0257298 10.1371/journal.pone.0257298
• Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach Cite
  Balogun TA, Iqbal MN, Saibu OA, Akintubosun MO, Lateef OM, Nneka UC, et al. Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach. Journal of Biomolecular Structure and Dynamics. Informa UK Limited; 2021;:1-13 10.1080/07391102.2021.1975570
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, et al. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology. Elsevier BV; 2021; 22:1139-1150 10.1016/s1470-2045(21)00288-6
• Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer Cite
  Nami B, Ghanaeian A, Black C, Wang Z. Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. Life. MDPI AG; 2021; 11:868 10.3390/life11090868
• Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes Cite
  Wetzel CL, Sutton TL, Gardiner S, Farinola M, Johnson N, Garreau JR. Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. Journal of Surgical Oncology. Wiley; 2021; 10.1002/jso.26646
• Metabolite Biomarkers of Response (BoRs): Towards a fingerprint for the evolution of metastatic breast cancer Cite
  Wolf J, Dong C, O'Day EM. Metabolite Biomarkers of Response (BoRs): Towards a fingerprint for the evolution of metastatic breast cancer. Progress in Biophysics and Molecular Biology. Elsevier BV; 2021; 10.1016/j.pbiomolbio.2021.08.005
• Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS randomized trial. Cite
  Thorat MA, Levey PM, Jones JL, Pinder SE, Bundred NJ, Fentiman IS, et al. Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS randomized trial.. Clinical Cancer Research. American Association for Cancer Research (AACR); 2021;:clincanres.1239.2021 10.1158/1078-0432.ccr-21-1239
• Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial Cite
  Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, et al. Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-766187/v1
• Mutant HER2 needs mutant HER3 to be an effective oncogene Cite
  Trenker R, Diwanji D, Jura N. Mutant HER2 needs mutant HER3 to be an effective oncogene. Cell Reports Medicine. Elsevier BV; 2021;:100361 10.1016/j.xcrm.2021.100361
• Clinicopathological features of and neoadjuvant therapy for HER2-positive classic invasive lobular carcinoma Cite
  Huang X, Chen H, Ding Q, Robinson MK, Moseley TW, Bassett IRL, et al. Clinicopathological features of and neoadjuvant therapy for HER2-positive classic invasive lobular carcinoma. Human Pathology. Elsevier BV; 2021; 10.1016/j.humpath.2021.07.010
• Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry Cite
  Yamada A, Kumamaru H, Shimizu C, Taira N, Nakayama K, Miyashita M, et al. Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry. European Journal of Cancer. Elsevier BV; 2021; 154:157-166 10.1016/j.ejca.2021.06.006
• Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer Cite
  Li Y, Wang S, Yang W, Liu H. Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer. Medicine. Ovid Technologies (Wolters Kluwer Health); 2021; 100:e26619 10.1097/md.0000000000026619
• Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR Cite
  Wulandari AA, Choiri AA, Fitria , Widiandani T. Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR. Journal of Basic and Clinical Physiology and Pharmacology. Walter de Gruyter GmbH; 2021; 32:393-401 10.1515/jbcpp-2020-0431
• Prevalence and characteristics of mouse mammary tumor virus-like virus associated breast cancer in China Cite
  Wang F, Zhang X, Yang M, Lin J, Yue Y, Li Y, et al. Prevalence and characteristics of mouse mammary tumor virus-like virus associated breast cancer in China. Infectious Agents and Cancer. Springer Science and Business Media LLC; 2021; 16 10.1186/s13027-021-00383-2
• Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis Cite
  Alanko J, Tanner M, Vanninen R, Auvinen A, Isola J. Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 187:267-274 10.1007/s10549-020-06060-z
• Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial Cite
  Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, et al. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06253-0
• HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases Cite
  Michel A, Oppong MD, Rauschenbach L, Pierscianek D, Dinger TF, Schmidt T, et al. HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases. World Neurosurgery. Elsevier BV; 2021; 10.1016/j.wneu.2021.05.096
• Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway Cite
  Kwon Y, Nam K, Kim S. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochemical Pharmacology. Elsevier BV; 2021;:114635 10.1016/j.bcp.2021.114635
• Investigating the composition and the anti-proliferative mechanism of a strawberry (Fragaria × ananassa) methanolic extract on in vitro murine breast cancer cells Cite
  Mazzoni L, Forbes-Hernandez T, Capocasa F. Investigating the composition and the anti-proliferative mechanism of a strawberry (Fragaria × ananassa) methanolic extract on in vitro murine breast cancer cells. Acta Horticulturae. International Society for Horticultural Science (ISHS); 2021;:1009-1016 10.17660/actahortic.2021.1309.143
• Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits Cite
  Wang B, Wang H, Zhao A, Zhang M, Yang J. Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-08267-9
• Evaluation of the antimetastatic and anticancer activities of morin in HER2‑overexpressing breast cancer SK‑BR‑3 cells Cite
  Lee K, Lee M, Nam K. Evaluation of the antimetastatic and anticancer activities of morin in HER2‑overexpressing breast cancer SK‑BR‑3 cells. Oncology Reports. Spandidos Publications; 2021; 46 10.3892/or.2021.8077
• Potential Diagnostic Significance of Salivary Copper Determination in Breast Cancer Patients: A Pilot Study Cite
  Bel’skaya LV, Sarf EA, Shalygin SP, Postnova TV, Kosenok VK. Potential Diagnostic Significance of Salivary Copper Determination in Breast Cancer Patients: A Pilot Study. Biological Trace Element Research. Springer Science and Business Media LLC; 2021; 10.1007/s12011-021-02710-5
• Identification of a Positive Association between Mammary Adipose Cholesterol Content and Indicators of Breast Cancer Aggressiveness in a French Population Cite
  Goupille C, Ouldamer L, Pinault M, Guimares C, Arbion F, Jourdan ML, et al. Identification of a Positive Association between Mammary Adipose Cholesterol Content and Indicators of Breast Cancer Aggressiveness in a French Population. The Journal of Nutrition. Oxford University Press (OUP); 2021; 10.1093/jn/nxaa432
• Dietary Inflammatory Potential and Risk of Breast Cancer: A Population-based Case-control Study in France (CECILE Study) Cite
  Hajji-Louati M, Cordina-Duverger E, Laouali N, Mancini F, Guénel P. Dietary Inflammatory Potential and Risk of Breast Cancer: A Population-based Case-control Study in France (CECILE Study). Research Square Platform LLC; 2021; 10.21203/rs.3.rs-397246/v1
• Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer Cite
  Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06192-w
• Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach Cite
  DuMond B, Patel V, Gross A, Fung A, Weber S. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. Journal of Oncology Pharmacy Practice. SAGE Publications; 2021;:107815522199971 10.1177/1078155221999712
• Predictors of Nodal Pathological Complete Response in Asian Women with Stage II–III Node-Positive Breast Cancer Cite
  Montagna G, Tong Y, Ritter M, Levi J, Weber WP, Chen X, et al. Predictors of Nodal Pathological Complete Response in Asian Women with Stage II–III Node-Positive Breast Cancer. Oncology. S. Karger AG; 2021;:1-6 10.1159/000513454
• Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer Cite
  Menendez JA, Papadimitropoulou A, Vander Steen T, Cuyàs E, Oza-Gajera BP, Verdura S, et al. Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers. MDPI AG; 2021; 13:1132 10.3390/cancers13051132
• Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review Cite
  Mansouri S, Mokhtari-Hesari P, Naghavi-al-Hosseini F, Seyednejad SA, Majidzadeh-A K, Moradi-kalbolandi S, et al. Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review. Pharmacological Reports. Springer Science and Business Media LLC; 2021; 10.1007/s43440-021-00237-z
• The Exciting New Field of HER2-Low Breast Cancer Treatment Cite
  Eiger D, Agostinetto E, Saúde-Conde R, de Azambuja E. The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers. MDPI AG; 2021; 13:1015 10.3390/cancers13051015
• Racial and Socioeconomic Disparities in Cardiotoxicity among Women with HER2-Positive Breast Cancer Cite
  Al-Sadawi M, Hussain Y, Copeland-Halperin RS, Tobin JN, Moskowitz CS, Dang CT, et al. Racial and Socioeconomic Disparities in Cardiotoxicity among Women with HER2-Positive Breast Cancer. The American Journal of Cardiology. Elsevier BV; 2021; 10.1016/j.amjcard.2021.02.013
• Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer Cite
  Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology. Springer Science and Business Media LLC; 2021; 10.1038/s41379-021-00738-5
• Effects of systemic inflammation on relapse in early breast cancer Cite
  McAndrew NP, Bottalico L, Mesaros C, Blair IA, Tsao PY, Rosado JM, et al. Effects of systemic inflammation on relapse in early breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-020-00212-6
• HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas Cite
  Shen T, Nitta H, Wei L, Parwani AV, Li Z. HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:519-527 10.1007/s10549-020-05650-1
• Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial Cite
  Samuel Martel , Matteo Lambertini , Dominique Agbor-Tarh , Noam F. Ponde , Andrea Gombos , Vicki Paterson , et al. Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. Journal of the National Comprehensive Cancer Network. National Comprehensive Cancer Network; 2021;:1-9. 10.6004/jnccn.2020.7606
• How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? Cite
  Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 28:287-294 10.1245/s10434-020-08593-5
• Her-2 Breast Cancer Outcomes Are Mitigated by Consuming n-3 Polyunsaturated, Saturated, and Monounsaturated Fatty Acids Compared to n-6 Polyunsaturated Fatty Acids Cite
  Hillyer LM, Hucik B, Baracuhy EM, Lin Z, Muller WJ, Robinson LE, et al. Her-2 Breast Cancer Outcomes Are Mitigated by Consuming n-3 Polyunsaturated, Saturated, and Monounsaturated Fatty Acids Compared to n-6 Polyunsaturated Fatty Acids. Nutrients. MDPI AG; 2020; 12:3901 10.3390/nu12123901
• Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study Cite
  Schiza A, Mauri D, Fredriksson I, Anna-Karin Wennstig , Valachis A. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-06022-5
• Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study Cite
  Li X, Zhang X, Liu J, Shen Y. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07593-8
• FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer Cite
  Gao JJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, et al. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020;:clincanres.3474.2020 10.1158/1078-0432.ccr-20-3474
• Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018) Cite
  Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O, et al. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018). European Journal of Cancer. Elsevier BV; 2020; 141:209-217 10.1016/j.ejca.2020.10.012
• Combined Broccoli Sprouts and Green Tea Polyphenols Contribute to the Prevention of Estrogen Receptor–Negative Mammary Cancer via Cell Cycle Arrest and Inducing Apoptosis in HER2/neu Mice Cite
  Li S, Wu H, Tollefsbol TO. Combined Broccoli Sprouts and Green Tea Polyphenols Contribute to the Prevention of Estrogen Receptor–Negative Mammary Cancer via Cell Cycle Arrest and Inducing Apoptosis in HER2/neu Mice. The Journal of Nutrition. Oxford University Press (OUP); 2020; 10.1093/jn/nxaa315
• Racial disparities in survival outcomes among breast cancer patients by molecular subtypes Cite
  Zhao F, Copley B, Niu Q, Liu F, Johnson JA, Sutton T, et al. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05984-w
• Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer Cite
  Dackus GMHE, Jóźwiak K, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, et al. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05978-8
• Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial Cite
  Di Cosimo S, Porcu L, Agbor-tarh D, Cinieri S, Franzoi MA, De Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01356-w
• Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity Cite
  Dahmani Z, Addou-Klouche L, Gizard F, Dahou S, Messaoud A, Chahinez Djebri N, et al. Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0240982 10.1371/journal.pone.0240982
• Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy Cite
  Ishitobi M, Matsuda N, Tazo M, Nakayama S, Tokui R, Ogawa T, et al. Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 10.1245/s10434-020-09176-0
• The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data Cite
  Modi ND, Tan JQE, Rowland A, Koczwara B, Kichenadasse G, McKinnon RA, et al. The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. Frontiers in Oncology. Frontiers Media SA; 2020; 10 10.3389/fonc.2020.01130
• Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer Cite
  Abdel-Razeq H, Edaily S, Iweir S, Salam M, Saleh Y, Sughayer M, et al. Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05942-6
• Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer Cite
  Van Raemdonck E, Floris G, Berteloot P, Laenen A, Vergote I, Wildiers H, et al. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05935-5
• Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients Cite
  Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, et al. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3743-3752 10.1200/jco.20.00184
• Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation Cite
  Layosa MAA, Lage NN, Chew BP, Atienza L, Mertens-Talcott S, Talcott S, et al. Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation. Nutrition and Cancer. Informa UK Limited; 2020;:1-13 10.1080/01635581.2020.1817514
• Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database Cite
  Nahleh ZA, Elimimian EB, Elson LC, Hobbs B, Wei W, Blake CN. Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2020; 14:117822342094569 10.1177/1178223420945694
• Docosahexaenoic acid (DHA) inhibits pro-angiogenic effects of breast cancer cells via down-regulating cellular and exosomal expression of angiogenic genes and microRNAs Cite
  Aslan C, Maralbashi S, Kahroba H, Asadi M, Soltani-Zangbar MS, Javadian M, et al. Docosahexaenoic acid (DHA) inhibits pro-angiogenic effects of breast cancer cells via down-regulating cellular and exosomal expression of angiogenic genes and microRNAs. Life Sciences. Elsevier BV; 2020; 258:118094 10.1016/j.lfs.2020.118094
• Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2020; 23:259 10.4048/jbc.2020.23.e34
• Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy Cite
  Hamy A, Darrigues L, Laas E, De Croze D, Topciu L, Lam G, et al. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0234191 10.1371/journal.pone.0234191
• Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype Cite
  Wilson HE, Stanton DA, Montgomery C, Infante AM, Taylor M, Hazard-Jenkins H, et al. Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-0162-2
• The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice Cite
  Asselin CY, Lam A, Cheung DYC, Eekhoudt CR, Zhu A, Mittal I, et al. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice. The Journal of Nutrition. Oxford University Press (OUP); 2020; 150:2353-2363 10.1093/jn/nxaa144
• Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT Cite
  Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, et al. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology. Radiological Society of North America (RSNA); 2020; 296:370-378 10.1148/radiol.2020192828
• A Polyphenol-Rich Muscadine Grape Extract Inhibits HER + Breast Cancer and Protects Against Trastuzumab-Induced Cardiotoxicity Cite
  Mackert J, Gallagher P, Tallant E. A Polyphenol-Rich Muscadine Grape Extract Inhibits HER + Breast Cancer and Protects Against Trastuzumab-Induced Cardiotoxicity. Current Developments in Nutrition. Oxford University Press (OUP); 2020; 4:334-334 10.1093/cdn/nzaa044_033
• Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy. Cite
  Tazo M, Kojima Y, Yoshida A, Nakayama S, Tokui R, Ogawa T, et al. Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12599-e12599 10.1200/jco.2020.38.15_suppl.e12599
• Antitumor potential of dark sweet cherry sweet (Prunus avium) phenolics in suppressing xenograft tumor growth of MDA-MB-453 breast cancer cells Cite
  Noratto G, Layosa MA, Lage NN, Atienza L, Ivanov I, Mertens-Talcott SU, et al. Antitumor potential of dark sweet cherry sweet (Prunus avium) phenolics in suppressing xenograft tumor growth of MDA-MB-453 breast cancer cells. The Journal of Nutritional Biochemistry. Elsevier BV; 2020; 84:108437 10.1016/j.jnutbio.2020.108437
• Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition Cite
  Saxena AR, Ilic Z, Sripada V, Crawford DR. Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition. Nutrition Research. Elsevier BV; 2020; 78:93-104 10.1016/j.nutres.2020.05.007
• Astaxanthin Modulates Apoptotic Molecules to Induce Death of SKBR3 Breast Cancer Cells Cite
  Kim MS, Ahn YT, Lee CW, Kim H, An WG. Astaxanthin Modulates Apoptotic Molecules to Induce Death of SKBR3 Breast Cancer Cells. Marine Drugs. MDPI AG; 2020; 18:266 10.3390/md18050266
• Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada Cite
  Rushton M, Lima I, Tuna M, Johnson C, Ivars J, Pritchard K, et al. Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 112:1222-1230 10.1093/jnci/djaa054
• Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam Cite
  Dang Cong T, Nguyen Thanh T, Nguyen Phan QA, Hoang Thi AP, Nguyen Tran BS, Nguyen Vu QH. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam. Asian Pacific Journal of Cancer Prevention. EpiSmart Science Vector Ltd; 2020; 21:1135-1142 10.31557/apjcp.2020.21.4.1135
• Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session Cite
  Deken MM, Kijanka MM, Beltrán Hernández I, Slooter MD, de Bruijn HS, van Diest PJ, et al. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release. Elsevier BV; 2020; 323:269-281 10.1016/j.jconrel.2020.04.030
• Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database Cite
  Fabiano V, Mandó P, Rizzo M, Ponce C, Coló F, Loza M, et al. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2020;:639-646 10.1200/jgo.19.00228
• Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study Cite
  Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, et al. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 122:1747-1753 10.1038/s41416-020-0815-9
• Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016 Cite
  Thomas A, Rhoads A, Suhl J, Conway KM, Hundley WG, McNally LR, et al. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. Clinical Breast Cancer. Elsevier BV; 2020; 20:e410-e422 10.1016/j.clbc.2020.01.014
• Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women Cite
  Marker KM, Zavala VA, Vidaurre T, Lott PC, Vásquez JN, Casavilca-Zambrano S, et al. Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. Cancer Research. American Association for Cancer Research (AACR); 2020; 80:1893-1901 10.1158/0008-5472.can-19-3659
• The effect of smoking on biological change of recurrent breast cancer Cite
  Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A, et al. The effect of smoking on biological change of recurrent breast cancer. Research Square; 2020; 10.21203/rs.2.23974/v1
• HER2 borderline is a negative prognostic factor for primary malignant breast cancer Cite
  Bhattacharjee A, Rajendra J, Dikshit R, Dutt S. HER2 borderline is a negative prognostic factor for primary malignant breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:225-231 10.1007/s10549-020-05608-3
• Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy Cite
  Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2020; 271:574-580 10.1097/sla.0000000000003126
• Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016 Cite
  Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. European Journal of Cancer. Elsevier BV; 2020; 129:60-70 10.1016/j.ejca.2020.01.016
• Abstract P6-08-21: Prevalence of HER2 positivity in germlineBRCA 1/2-associated breast cancers (gBRCA1/2-BC) Cite
  Whitaker K, Obeid E, Goldstein L, Daly M. Abstract P6-08-21: Prevalence of HER2 positivity in germlineBRCA 1/2-associated breast cancers (gBRCA1/2-BC). Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p6-08-21
• What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer? Cite
  Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M. What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 26:2783-2788 10.1158/1078-0432.ccr-19-2612
• Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis Cite
  Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 26:2838-2848 10.1158/1078-0432.ccr-19-3492
• Breast Cancer With Brain Metastases: Perspective From a Long-Term Survivor Cite
  Kofron CP, Chapman A. Breast Cancer With Brain Metastases: Perspective From a Long-Term Survivor. Integrative Cancer Therapies. SAGE Publications; 2020; 19:153473541989001 10.1177/1534735419890017
• Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis Cite
  Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, et al. Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. General Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-gs5-01
• Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01) Cite
  Stankowski-Drengler TJ, Schumacher JR, Hanlon B, Livingston-Rosanoff D, Van de Walle K, Greenberg CC, et al. Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:637-644 10.1245/s10434-019-07846-2
• Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States Cite
  Sung H, DeSantis C, Jemal A. Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States. JNCI Cancer Spectrum. Oxford University Press (OUP); 2019; 4 10.1093/jncics/pkz091
• Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Cite
  Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. British Journal of Cancer. Springer Science and Business Media LLC; 2019; 121:991-1000 10.1038/s41416-019-0619-y
• Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older Cite
  Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, et al. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:687-697 10.1007/s10549-019-05505-4
• Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy Cite
  Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Sugae S, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. European Journal of Surgical Oncology. Elsevier BV; 2019; 45:2289-2294 10.1016/j.ejso.2019.08.001
• Dark sweet cherry (Prunus avium) phenolics enriched in anthocyanins exhibit enhanced activity against the most aggressive breast cancer subtypes without toxicity to normal breast cells Cite
  Lage NN, Layosa MAA, Arbizu S, Chew BP, Pedrosa ML, Mertens-Talcott S, et al. Dark sweet cherry (Prunus avium) phenolics enriched in anthocyanins exhibit enhanced activity against the most aggressive breast cancer subtypes without toxicity to normal breast cells. Journal of Functional Foods. Elsevier BV; 2019; 64:103710 10.1016/j.jff.2019.103710
• Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects Cite
  Tang S, Deng X, Zhou J, Li Q, Ge X, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomedicine & Pharmacotherapy. Elsevier BV; 2019; 121:109604 10.1016/j.biopha.2019.109604
• Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016) Cite
  Tang M, Schaffer A, Kiely BE, Daniels B, Simes RJ, Lee CK, et al. Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016). British Journal of Cancer. Springer Science and Business Media LLC; 2019; 121:904-911 10.1038/s41416-019-0612-5
• Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 Cite
  Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, et al. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:3425-3435 10.1200/jco.19.00443
• Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study Cite
  Jeong SH, An Y, Ahn C, Park B, Lee MH, Noh D, et al. Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:459-470 10.1007/s10549-019-05451-1
• Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics Cite
  Blair CK, Wiggins CL, Nibbe AM, Storlie CB, Prossnitz ER, Royce M, et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. npj Breast Cancer. Springer Science and Business Media LLC; 2019; 5 10.1038/s41523-019-0128-4
• Revisit the risk factors of recurrence in node involved HER2-positive breast cancer Cite
  Hasegawa Y, Kogawa T, Shimokawa M, Kusuhara S, Fujimoto Y, Harano K, et al. Revisit the risk factors of recurrence in node involved HER2-positive breast cancer. Annals of Oncology. Elsevier BV; 2019; 30:vi114 10.1093/annonc/mdz338.102
• Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials Cite
  Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer J, Seiler S, et al. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials. Annals of Oncology. Elsevier BV; 2019; 30:v62-v63 10.1093/annonc/mdz240.014
• Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models Cite
  Gupta P, Srivastava SK. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Medicine. Springer Science and Business Media LLC; 2012; 10 10.1186/1741-7015-10-80
• HPV DNA Associates With Breast Cancer Malignancy and It Is Transferred to Breast Cancer Stromal Cells by Extracellular Vesicles Cite
  De Carolis S, Storci G, Ceccarelli C, Savini C, Gallucci L, Sansone P, et al. HPV DNA Associates With Breast Cancer Malignancy and It Is Transferred to Breast Cancer Stromal Cells by Extracellular Vesicles. Frontiers in Oncology. Frontiers Media SA; 2019; 9 10.3389/fonc.2019.00860
• Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties Cite
  Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3920-3930 10.1245/s10434-019-07653-9
• Abstract 296: Trastuzumab sensitizes HER2+ breast cancer to increase efficacy of chemotherapyin vitroandin vivo Cite
  Shah A, Jarrett A, Syed A, Yankeelov T, Sorace A. Abstract 296: Trastuzumab sensitizes HER2+ breast cancer to increase efficacy of chemotherapyin vitroandin vivo. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-296
• Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment Cite
  Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology. Springer Science and Business Media LLC; 2019; 42:815-828 10.1007/s13402-019-00464-w
• Abstract 4810: Olive oil-derived (-)-oleocanthal for prevention of breast cancer recurrence Cite
  Siddique AB, Ayoub NM, Sayed KAE. Abstract 4810: Olive oil-derived (-)-oleocanthal for prevention of breast cancer recurrence. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-4810
• Abstract 1860: Muscadine grape extract prevents proliferation of trastuzumab-sensitive and -resistant HER2 positive breast cancer cells and has synergistic effects when combined with trastuzumab Cite
  Mackert J, Gallagher PE, Tallant EA. Abstract 1860: Muscadine grape extract prevents proliferation of trastuzumab-sensitive and -resistant HER2 positive breast cancer cells and has synergistic effects when combined with trastuzumab. Cancer Chemistry. American Association for Cancer Research; 2019; 10.1158/1538-7445.am2019-1860
• Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer Cite
  Takada K, Kashiwagi S, Asano Y, Goto W, Takahashi K, Fujita H, et al. Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-5828-5
• Dark Sweet Cherry (Prunus Avium L.) Phenolics Induce Apoptosis and Inhibit Invasion on Breast Cancer MDA-MB-453 Through MAPK-dependent and Independent Pathways (P05-007-19) Cite
  Layosa MA, Lage N, Talcott S, Talcott S, Atienza L, Chew B, et al. Dark Sweet Cherry (Prunus Avium L.) Phenolics Induce Apoptosis and Inhibit Invasion on Breast Cancer MDA-MB-453 Through MAPK-dependent and Independent Pathways (P05-007-19). Current Developments in Nutrition. Oxford University Press (OUP); 2019; 3 10.1093/cdn/nzz030.p05-007-19
• Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification Cite
  Horimoto Y, Terao T, Tsutsumi Y, Tanabe M, Mogushi K, Hlaing MT, et al. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification. The American Journal of Surgical Pathology. Ovid Technologies (Wolters Kluwer Health); 2019; 43:1221-1228 10.1097/pas.0000000000001300
• Clinical Outcomes in HER2-positive Lobular Breast Cancer: a Single-institution Experience Cite
  Irfan T, Asare B, Mohammed K, Osin P, Nerurkar A, Smith I, et al. Clinical Outcomes in HER2-positive Lobular Breast Cancer: a Single-institution Experience. Clinical Oncology. Elsevier BV; 2019; 31:e109-e110 10.1016/j.clon.2019.03.020
• Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer Cite
  Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2019; 73:2859-2868 10.1016/j.jacc.2019.03.495
• Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial Cite
  Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, et al. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 177:103-114 10.1007/s10549-019-05284-y
• The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer Cite
  VOGEL C, MALTER W, MORGENSTERN B, LUDWIG S, VEHRESCHILD JJ, HAMACHER S, et al. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. Anticancer Research. Anticancer Research USA Inc.; 2019; 39:2647-2659 10.21873/anticanres.13389
• The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution Cite
  Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, et al. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer. Springer Science and Business Media LLC; 2019; 120:1075-1082 10.1038/s41416-019-0436-3
• Thymoquinone Augments Cyclophosphamide-Mediated Inhibition of Cell Proliferation in Breast Cancer Cells Cite
  Khan A, Aldebasy YH, Alsuhaibani SA, Khan MA. Thymoquinone Augments Cyclophosphamide-Mediated Inhibition of Cell Proliferation in Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention. EpiSmart Science Vector Ltd; 2019; 20:1153-1160 10.31557/apjcp.2019.20.4.1153
• Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy Cite
  Lee A, Jo S, Lee C, Shin H, Kim TH, Ahn KJ, et al. Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy. Breast Cancer. Springer Science and Business Media LLC; 2019; 26:672-680 10.1007/s12282-019-00967-2
• Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Cite
  von Minckwitz G, Huang C, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2019; 380:617-628 10.1056/nejmoa1814017
• Loss of HER2 after HER2-targeted treatment Cite
  Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:401-408 10.1007/s10549-019-05173-4
• Abstract P5-18-04: HER2 overexpression in ductal carcinoma in situ: A biomarker for risk stratification and therapeutic implication Cite
  Yin J, Gascard P, Last B, Singh M, Tlsty T, Tjoe J. Abstract P5-18-04: HER2 overexpression in ductal carcinoma in situ: A biomarker for risk stratification and therapeutic implication. Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p5-18-04
• Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy Cite
  Wang X, He Y, Fan Z, Wang T, Xie Y, Li J, et al. Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy. Breast Care. S. Karger AG; 2019; 14:388-393 10.1159/000495186
• Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial) Cite
  Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, et al. Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p1-11-21
• (−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo Cite
  Siddique A, Ebrahim H, Akl M, Ayoub N, Goda A, Mohyeldin M, et al. (−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo. Nutrients. MDPI AG; 2019; 11:412 10.3390/nu11020412
• Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens? Cite
  Greer LT, Rosman M, Mylander WC, Hooke J, Kovatich A, Sawyer K, et al. Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?. Journal of the American College of Surgeons. Elsevier BV; 2013; 216:239-251 10.1016/j.jamcollsurg.2012.09.007
• Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy Cite
  Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology. Elsevier BV; 2018; 35:153-159 10.1016/j.cjca.2018.11.028
• Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells Cite
  Abdullah ML, Hafez MM, Al-Hoshani A, Al-Shabanah O. Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells. BMC Complementary and Alternative Medicine. Springer Science and Business Media LLC; 2018; 18 10.1186/s12906-018-2392-5
• Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011 Cite
  Malmgren J, Hurlbert M, Atwood M, Kaplan HG. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:505-514 10.1007/s10549-018-05090-y
• A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study Cite
  Lidbrink E, Chmielowska E, Otremba B, Bouhlel A, Lauer S, Liste Hermoso M, et al. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:187-196 10.1007/s10549-018-5058-6
• Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype Cite
  Leone J, Zwenger AO, Leone BA, Vallejo CT, Leone JP. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype. American Journal of Clinical Oncology. Ovid Technologies (Wolters Kluwer Health); 2019; 42:215-220 10.1097/coc.0000000000000497
• HER2 positive rates in invasive lobular breast carcinoma: A study amongst 1,095 consecutive Asian patients Cite
  Kee G, Tan R, Sultana R, Zaw M, Lian W, Tan K, et al. HER2 positive rates in invasive lobular breast carcinoma: A study amongst 1,095 consecutive Asian patients. Annals of Oncology. Elsevier BV; 2018; 29:ix1 10.1093/annonc/mdy426.002
• Fisetin induces apoptosis in breast cancer MDA‐MB‐453 cells through degradation of HER2/neu and via the PI3K/Akt pathway Cite
  Guo G, Zhang W, Dang M, Yan M, Chen Z. Fisetin induces apoptosis in breast cancer MDA‐MB‐453 cells through degradation of HER2/neu and via the PI3K/Akt pathway. Journal of Biochemical and Molecular Toxicology. Wiley; 2018; 33:e22268 10.1002/jbt.22268
• Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Cite
  Resende U, Cabello C, Oliveira Botelho Ramalho S, Zeferino L. Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Oncology. S. Karger AG; 2018; 95:229-238 10.1159/000489785
• Breast Cancer Mortality in Older and Younger Patients in California Cite
  Tao L, Schwab RB, San Miguel Y, Gomez SL, Canchola AJ, Gago-Dominguez M, et al. Breast Cancer Mortality in Older and Younger Patients in California. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2018; 28:303-310 10.1158/1055-9965.epi-18-0353
• Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women Cite
  Yoon TI, Kwak BS, Yi OV, Kim S, Um E, Yun KW, et al. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 173:657-665 10.1007/s10549-018-5031-4
• Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study Cite
  van Maaren MC, de Munck L, Strobbe LJ, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. International Journal of Cancer. Wiley; 2018; 144:263-272 10.1002/ijc.31914
• Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery Cite
  Nakashima K, Uematsu T, Takahashi K, Nishimura S, Tadokoro Y, Hayashi T, et al. Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer. Springer Science and Business Media LLC; 2018; 26:206-214 10.1007/s12282-018-0914-0
• Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy Cite
  Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, et al. Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy. The Oncologist. Wiley; 2018; 24:313-318 10.1634/theoncologist.2018-0213
• Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues Cite
  Ma Z, Parris AB, Howard EW, Shi Y, Yang S, Jiang Y, et al. Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues. Carcinogenesis. Oxford University Press (OUP); 2018; 39:1264-1273 10.1093/carcin/bgy096
• Abstract B30: Bovine leukemia virus in breast tissue linked to increased cell proliferation and breast cancer risk Cite
  Buehring GC, Shen H, Baltzell K, Sison J, Krishnamurty S, Lendez P, et al. Abstract B30: Bovine leukemia virus in breast tissue linked to increased cell proliferation and breast cancer risk. Metabolism. American Association for Cancer Research; 2018; 10.1158/1557-3125.advbc17-b30
• Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile Cite
  Takahashi S, Thike AA, Koh VCY, Sasano H, Tan PH. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Archiv. Springer Science and Business Media LLC; 2018; 473:275-283 10.1007/s00428-018-2416-z
• Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow‐up Cite
  Farvid MS, Chen WY, Rosner BA, Tamimi RM, Willett WC, Eliassen AH. Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow‐up. International Journal of Cancer. Wiley; 2018; 144:1496-1510 10.1002/ijc.31653
• Abstract 2683: The olive-based oleocanthal as a dual HER2-MET inhibitor for the control of breast cancer recurrence Cite
  Siddique AB, Ebrahim H, Mohyeldin M, Jois SD, Sayed KAE. Abstract 2683: The olive-based oleocanthal as a dual HER2-MET inhibitor for the control of breast cancer recurrence. Cancer Chemistry. American Association for Cancer Research; 2018; 10.1158/1538-7445.am2018-2683
• The inhibitory activity of peonidin purple sweet potato in human epidermal receptor-2 receptor (her-2) expression by in silico study Cite
  Laksmiani NPL, Widiastari MI, Reynaldi KR. The inhibitory activity of peonidin purple sweet potato in human epidermal receptor-2 receptor (her-2) expression by in silico study. Journal of Physics: Conference Series. IOP Publishing; 2018; 1040:012010 10.1088/1742-6596/1040/1/012010
• Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Cite
  Choi JY, Cho EY, Choi YJ, Lee JH, Jung SP, Cho KR, et al. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:181-188 10.1007/s10549-018-4809-8
• Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study Cite
  Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, et al. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study. Clinical Cancer Research. American Association for Cancer Research (AACR); 2018; 24:3593-3601 10.1158/1078-0432.ccr-18-0201
• Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Cite
  Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer. Elsevier BV; 2018; 96:17-24 10.1016/j.ejca.2018.03.015
• Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy Cite
  Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:559-567 10.1007/s10549-018-4801-3
• Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells Cite
  Chen J, Zhu Y, Zhang W, Peng X, Zhou J, Li F, et al. Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4231-y
• Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer Cite
  Paralta Branco F, Silva F, André S, Catarino A, Madureira R, Moreira Pinto J, et al. Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer. European Journal of Cancer. Elsevier BV; 2018; 92:S94 10.1016/s0959-8049(18)30510-0
• Breast cancer-specific survival by age: Worse outcomes for the oldest patients Cite
  Freedman RA, Keating NL, Lin NU, Winer EP, Vaz-Luis I, Lii J, et al. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. Wiley; 2018; 124:2184-2191 10.1002/cncr.31308
• Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3 Cite
  Di Y, De Silva F, Krol ES, Alcorn J. Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3. Nutrition and Cancer. Informa UK Limited; 2018; 70:306-315 10.1080/01635581.2018.1421677
• Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients Cite
  Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:35-43 10.1007/s10549-018-4730-1
• Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes Cite
  Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Investigational New Drugs. Springer Science and Business Media LLC; 2018; 36:782-796 10.1007/s10637-018-0568-y
• Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer Cite
  Mamtani A, Gonzalez JJ, Neo DT, Friedman RS, Recht A, Hacker MR, et al. Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2018; 25:1495-1501 10.1245/s10434-018-6350-8
• HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance Cite
  Liu S, Lee JS, Jie C, Park MH, Iwakura Y, Patel Y, et al. HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance. Cancer Research. American Association for Cancer Research (AACR); 2018; 78:2040-2051 10.1158/0008-5472.can-17-2761
• HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors Cite
  Daemen A, Manning G. HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-0933-y
• Cucurbitacin D exhibits its anti-cancer effect in human breast cancer cells by inhibiting Stat3 and Akt signaling Cite
  Ku JM, Hong SH, Kim HI, Lim YS, Lee SJ, Kim M, et al. Cucurbitacin D exhibits its anti-cancer effect in human breast cancer cells by inhibiting Stat3 and Akt signaling. European Journal of Inflammation. SAGE Publications; 2018; 16:1721727X1775180 10.1177/1721727x17751809
• Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2 Cite
  Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3942-3948 10.1200/jco.2017.74.1165
• De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype Cite
  Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2017; 34:457-465 10.1007/s10585-017-9871-9
• Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Cite
  Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2017; 18:e687-e694 10.1016/j.clbc.2017.11.012
• Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease? Cite
  Tong Y, Chen X, Fei X, Lin L, Wu J, Huang O, et al. Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. European Journal of Cancer. Elsevier BV; 2018; 89:9-18 10.1016/j.ejca.2017.10.033
• The prognostic role of tumor size in early breast cancer in the era of molecular biology Cite
  Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, et al. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0189127 10.1371/journal.pone.0189127
• Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer Cite
  Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, et al. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. The Breast. Elsevier BV; 2018; 37:142-147 10.1016/j.breast.2017.11.004
• Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients Cite
  Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients. Clinical Breast Cancer. Elsevier BV; 2018; 18:e687-e694 10.1016/j.clbc.2017.11.012
• Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial Cite
  Sjöström M, Lundstedt D, Hartman L, Holmberg E, Killander F, Kovács A, et al. Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3222-3229 10.1200/jco.2017.72.7263
• Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes Cite
  Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, Miramón J, et al. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. Modern Pathology. Springer Science and Business Media LLC; 2017; 31:299-306 10.1038/modpathol.2017.129
• Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study Cite
  Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, et al. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:479-483 10.1007/s10549-017-4526-8
• Silibinin: An Inhibitor of Mir-181a Gene Expression in Sk-Br-3 Breast Cancer Cell Line Cite
  Shahinfar P, Motamed N, Birjandian E, Shabanpour O. Silibinin: An Inhibitor of Mir-181a Gene Expression in Sk-Br-3 Breast Cancer Cell Line. Indian Journal of Pharmaceutical Education and Research. EManuscript Services; 2017; 51:597-602 10.5530/ijper.51.4.89
• Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer Cite
  De Gregorio A, Friedl TW, Huober J, Scholz C, De Gregorio N, Rack B, et al. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology. American Society of Clinical Oncology (ASCO); 2017;:1-12 10.1200/po.17.00023
• Bisphenol A induces proliferative effects on both breast cancer cells and vascular endothelial cells through a shared GPER-dependent pathway in hypoxia Cite
  Xu F, Wang X, Wu N, He S, Yi W, Xiang S, et al. Bisphenol A induces proliferative effects on both breast cancer cells and vascular endothelial cells through a shared GPER-dependent pathway in hypoxia. Environmental Pollution. Elsevier BV; 2017; 231:1609-1620 10.1016/j.envpol.2017.09.069
• Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population Cite
  Liu YL, Saraf A, Catanese B, Lee SM, Zhang Y, Connolly EP, et al. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:277-288 10.1007/s10549-017-4507-y
• The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer Cite
  Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, et al. The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/s41598-017-10414-x
• HER2+breast cancer cells undergo apoptosis upon exposure to tannic acid released from remodeled cross-linked collagen type I Cite
  Jordan LG, Booth BW. HER2+breast cancer cells undergo apoptosis upon exposure to tannic acid released from remodeled cross-linked collagen type I. Journal of Biomedical Materials Research Part A. Wiley; 2017; 106:26-32 10.1002/jbm.a.36205
• Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer Cite
  Mustafa RE, DeStefano LM, Bahng J, Yoon-Flannery K, Fisher CS, Zhang PJ, et al. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2999-3003 10.1245/s10434-017-5941-0
• Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer Cite
  Yoshida A, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. Journal of Surgical Oncology. Wiley; 2017; 116:1021-1028 10.1002/jso.24762
• Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype Cite
  McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:3124-3132 10.1245/s10434-017-6021-1
• Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia Cite
  Gallagher EJ, Zelenko Z, Neel BA, Antoniou IM, Rajan L, Kase N, et al. Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia. Oncogene. Springer Science and Business Media LLC; 2017; 36:6462-6471 10.1038/onc.2017.247
• The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy Cite
  Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, et al. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. Wiley; 2017; 24:148-153 10.1111/tbj.12853
• The Association of Mammographic Density and Molecular Breast Cancer Subtype Cite
  Edwards BL, Atkins KA, Stukenborg GJ, Novicoff WM, Larson KN, Cohn WF, et al. The Association of Mammographic Density and Molecular Breast Cancer Subtype. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 26:1487-1492 10.1158/1055-9965.epi-16-0881
• Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors Cite
  Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:743-750 10.1007/s10549-017-4383-5
• Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro Cite
  Goyette S, Liang Y, Mafuvadze B, Cook M, Munir M, Hyder S. Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro. Breast Cancer: Targets and Therapy. Informa UK Limited; 2017; Volume 9:347-357 10.2147/bctt.s135371
• Abstract 1077: Extra-virgin olive oil Met inhibitor oleocanthal-lapatinib: a novel synergistic combination for HER2-dependent breast malignancies Cite
  Siddique AB, Ebrahim HY, Akl MR, Mohyeldin MM, Sayed KAE. Abstract 1077: Extra-virgin olive oil Met inhibitor oleocanthal-lapatinib: a novel synergistic combination for HER2-dependent breast malignancies. Cancer Chemistry. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-1077
• De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance Cite
  Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, et al. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. The Breast. Elsevier BV; 2017; 34:S19-S26 10.1016/j.breast.2017.06.022
• Radiation therapy utilization and outcomes for older women with breast cancer: Impact of molecular subtype and tumor grade Cite
  Haque W, Kee Yuan DM, Verma V, Butler EB, Teh BS, Wiederhold L, et al. Radiation therapy utilization and outcomes for older women with breast cancer: Impact of molecular subtype and tumor grade. The Breast. Elsevier BV; 2017; 35:34-41 10.1016/j.breast.2017.06.011
• The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment Cite
  Ayoub NM, Siddique AB, Ebrahim HY, Mohyeldin MM, El Sayed KA. The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. European Journal of Pharmacology. Elsevier BV; 2017; 810:100-111 10.1016/j.ejphar.2017.06.019
• Breast cancer phenotype in patients with hereditary gene mutations other than BRCA1 and BRCA2. Cite
  Arun B, Elsayegh N, Lin HY, Clifton K, Gutierrez-Barrera AM, Litton JK, et al. Breast cancer phenotype in patients with hereditary gene mutations other than BRCA1 and BRCA2.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:e13121-e13121 10.1200/jco.2017.35.15_suppl.e13121
• Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study Cite
  Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. Impact Journals, LLC; 2017; 8:27990-27996 10.18632/oncotarget.15856
• Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials Cite
  Yerushalmi R, Dong B, Chapman J, Goss P, Pollak M, Burnell M, et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Annals of Oncology. Elsevier BV; 2017; 28:1560-1568 10.1093/annonc/mdx152
• Piperlongumine downregulates the expression of HER family in breast cancer cells Cite
  Jin H, Park J, Kim H, Chang YH, Hong YJ, Park I, et al. Piperlongumine downregulates the expression of HER family in breast cancer cells. Biochemical and Biophysical Research Communications. Elsevier BV; 2017; 486:1083-1089 10.1016/j.bbrc.2017.03.166
• Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice Cite
  Lim YJ, Lee S, Choi N, Kwon J, Eom K, Kang E, et al. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:555-563 10.1007/s10549-017-4206-8
• Breast cancer subtype distribution is different in normal weight, overweight, and obese women Cite
  Gershuni V, Li YR, Williams AD, So A, Steel L, Carrigan E, et al. Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:375-381 10.1007/s10549-017-4192-x
• Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Cite
  Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Fumagalli D, et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1421-1429 10.1200/jco.2016.69.7722
• Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany Cite
  Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, et al. Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. The Oncologist. Wiley; 2017; 22:131-138 10.1634/theoncologist.2016-0193
• Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective Cite
  Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0172731 10.1371/journal.pone.0172731
• Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab Cite
  Blanchette P, Desautels D, Pond G, Bartlett J, Nofech-Mozes S, Yaffe M, et al. Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p6-09-30
• Abstract P5-16-21: The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients Cite
  Lillemoe T, Susnik B, Grimm E, Kang S, Swenson K, Krueger J, et al. Abstract P5-16-21: The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p5-16-21
• Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients Cite
  Aktas B, Westerwick D, Mairinger F, Kasimir-Bauer S, Kimmig R, Schmid K, et al. Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p1-01-09
• Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells Cite
  Lewinska A, Adamczyk-Grochala J, Kwasniewicz E, Deregowska A, Wnuk M. Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells. Apoptosis. Springer Science and Business Media LLC; 2017; 22:800-815 10.1007/s10495-017-1353-7
• Abstract PD8-02: Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry Cite
  Martinez M, Cress R, Gomez S, Rodriguez D, Cook L, Schwab R, et al. Abstract PD8-02: Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry. Poster Discussion Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-pd8-02
• Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials Cite
  Hao S, Tian W, Gao B, Jiang Y, Zhang X, Zhang S, et al. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials. Oncotarget. Impact Journals, LLC; 2017; 8:19923-19933 10.18632/oncotarget.15252
• 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Cite
  Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. Elsevier BV; 2017; 389:1195-1205 10.1016/s0140-6736(16)32616-2
• Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice Cite
  Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice. Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2017; 36 10.1186/s13046-017-0498-0
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype Cite
  Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1049-1060 10.1200/jco.2015.63.1010
• Induction of G2M Arrest by Flavokawain A, A Kava Chalcone, Increases the Responsiveness of HER2 Overexpressing Breast Cancer Cells to Herceptin Cite
  Jandial DD, Krill LS, Chen L, Wu C, Ke Y, Xie J, et al. Induction of G2M Arrest by Flavokawain A, A Kava Chalcone, Increases the Responsiveness of HER2 Overexpressing Breast Cancer Cells to Herceptin. MDPI AG; 2017; 10.20944/preprints201701.0098.v1
• Cytotoxic activities of five compounds with high polarity in BT-474 breast cancer cell line by NRU and MTT assays Cite
  Bacanli M, Anlar H, Basaran N, Basaran A. Cytotoxic activities of five compounds with high polarity in BT-474 breast cancer cell line by NRU and MTT assays. Planta Medica. Georg Thieme Verlag KG; 2016; 81:S1-S381 10.1055/s-0036-1596935
• The Relationships between HER2 Overexpression and DCIS Characteristics Cite
  Di Cesare P, Pavesi L, Villani L, Battaglia A, Da Prada GA, Riccardi A, et al. The Relationships between HER2 Overexpression and DCIS Characteristics. The Breast Journal. Wiley; 2016; 23:307-314 10.1111/tbj.12735
• Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer Cite
  Grosset A, Poirier F, Gaboury L, St-Pierre Y. Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0166731 10.1371/journal.pone.0166731
• More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials Cite
  Vasista A, Stockler M, West T, Wilcken N, Kiely B. More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. The Breast. Elsevier BV; 2017; 31:99-104 10.1016/j.breast.2016.10.007
• Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy Cite
  Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 161:173-179 10.1007/s10549-016-4031-5
• Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology) Cite
  Kaplan MA, Arslan UY, Işıkdogan A, Dane F, Oksuzoglu B, Inanc M, et al. Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). Breast Care. S. Karger AG; 2016; 11:248-252 10.1159/000448186
• The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients Cite
  Lee MH, Jung S, Kang SH, Song EJ, Park IH, Kong S, et al. The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0163370 10.1371/journal.pone.0163370
• Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database Cite
  Liu J, Chen K, Jiang W, Mao K, Li S, Kim MJ, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2016; 143:161-168 10.1007/s00432-016-2281-6
• Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer Cite
  Kim HS, Jung M, Choi SK, Moon WK, Kim SJ. Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0160835 10.1371/journal.pone.0160835
• Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer Cite
  Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:487-493 10.1016/j.clbc.2016.07.013
• Detection of human papillomavirus-16 DNA in archived clinical samples of breast and lung cancer patients from North Pakistan Cite
  Ilahi NE, Anwar S, Noreen M, Hashmi SN, Murad S. Detection of human papillomavirus-16 DNA in archived clinical samples of breast and lung cancer patients from North Pakistan. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2016; 142:2497-2502 10.1007/s00432-016-2251-z
• Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies Cite
  Warner ET, Hu R, Collins LC, Beck AH, Schnitt S, Rosner B, et al. Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies. Cancer Prevention Research. American Association for Cancer Research (AACR); 2016; 9:732-738 10.1158/1940-6207.capr-16-0085
• Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013 Cite
  Thomas A, Weigel RJ, Lynch CF, Spanheimer PM, Breitbach EK, Schroeder MC. Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013. The American Journal of Surgery. Elsevier BV; 2017; 214:323-328 10.1016/j.amjsurg.2016.08.008
• HER2 expression identifies dynamic functional states within circulating breast cancer cells Cite
  Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. Springer Science and Business Media LLC; 2016; 537:102-106 10.1038/nature19328
• Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu Cite
  Fry EA, Taneja P, Inoue K. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu. International Journal of Cancer. Wiley; 2016; 140:495-503 10.1002/ijc.30399
• Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients Cite
  Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, et al. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2578-5
• Patterns of change over time and history of the inflammatory potential of diet and risk of breast cancer among postmenopausal women Cite
  Tabung FK, Steck SE, Liese AD, Zhang J, Ma Y, Johnson KC, et al. Patterns of change over time and history of the inflammatory potential of diet and risk of breast cancer among postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:139-149 10.1007/s10549-016-3925-6
• Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer Cite
  Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:367-374 10.1007/s10549-016-3933-6
• Abstract CT086: Omega-3 fatty acids and ERPR(-) and HER-2/neu(+) breast cancer prevention Cite
  Yee LD, Lester JL, Straka SR, Woelke S, Ke J, Shen R, et al. Abstract CT086: Omega-3 fatty acids and ERPR(-) and HER-2/neu(+) breast cancer prevention. Clinical Trials. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-ct086
• Abstract 1759: The association between alcohol, physical activity and breast cancer subtypes in a nested case-control study from the Norwegian Breast Cancer Screening Program Cite
  Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Abstract 1759: The association between alcohol, physical activity and breast cancer subtypes in a nested case-control study from the Norwegian Breast Cancer Screening Program. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-1759
• Abstract 1747: Relationships between anthropometric and reproductive factors and risks of triple-negative and HER2-overexpressing breast cancers Cite
  Li CI, Chen L, Tang M, Porter P, Cook L. Abstract 1747: Relationships between anthropometric and reproductive factors and risks of triple-negative and HER2-overexpressing breast cancers. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-1747
• Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors Cite
  Chandrika BB, Steephan M, Kumar TS, Sabu A, Haridas M. Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors. Life Sciences. Elsevier BV; 2016; 160:47-56 10.1016/j.lfs.2016.07.007
• Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells Cite
  Ma J, Hung C, Lin Y, Ho C, Kao J, Way T. Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget. Impact Journals, LLC; 2016; 7:58915-58930 10.18632/oncotarget.10410
• The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Cite
  van Ramshorst MS, van der Heiden-van der Loo M, Dackus GMHE, Linn SC, Sonke GS. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 158:361-371 10.1007/s10549-016-3878-9
• Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes Cite
  Rondón-Lagos M, Rangel N, Di Cantogno LV, Annaratone L, Castellano I, Russo R, et al. Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. Endocrine-Related Cancer. Bioscientifica; 2016; 23:635-650 10.1530/erc-16-0078
• Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study Cite
  Doebar SC, van den Broek EC, Koppert LB, Jager A, Baaijens MHA, Obdeijn IAM, et al. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 158:179-187 10.1007/s10549-016-3862-4
• The association of age with breast cancer mortality within four race/ethnicities for the triple negative and HER2-overexpressing subtypes. Cite
  Parise C, Caggiano V. The association of age with breast cancer mortality within four race/ethnicities for the triple negative and HER2-overexpressing subtypes.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1073-1073 10.1200/jco.2016.34.15_suppl.1073
• Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients. Cite
  Sanford RA, Lei X, Giordano SH, Tripathy D, Barcenas CH, Chavez-Mac Gregor M. Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1038-1038 10.1200/jco.2016.34.15_suppl.1038
• HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo Cite
  Hou J, Zhou Z, Chen X, Zhao R, Yang Z, Wei N, et al. HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget. Impact Journals, LLC; 2016; 7:45186-45198 10.18632/oncotarget.9870
• Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer Cite
  Chen L, Cook LS, Tang MC, Porter PL, Hill DA, Wiggins CL, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:545-554 10.1007/s10549-016-3825-9
• Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer Cite
  Parkinson B, Viney R, Haas M, Goodall S, Srasuebkul P, Pearson S. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer. PharmacoEconomics. Springer Science and Business Media LLC; 2016; 34:1039-1050 10.1007/s40273-016-0411-2
• Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells Cite
  SEO H, KU JM, CHOI H, CHOI YK, WOO J, KIM M, et al. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells. Oncology Reports. Spandidos Publications; 2016; 36:31-42 10.3892/or.2016.4786
• Abstract B31: In utero exposure to bisphenol A induces reprogramming of mammary development and tumor risk in MMTV-erbB-2 transgenic mice Cite
  Ma Z, Parris A, Yang X. Abstract B31: In utero exposure to bisphenol A induces reprogramming of mammary development and tumor risk in MMTV-erbB-2 transgenic mice. Other Topics. American Association for Cancer Research; 2016; 10.1158/1557-3125.devbiolca15-b31
• Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer Cite
  Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S, et al. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:e133-e140 10.1016/j.clbc.2016.05.014
• Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy Cite
  Villarreal-Garza C, Bargallo-Rocha JE, Soto-Perez-de-Celis E, Lasa-Gonsebatt F, Arce-Salinas C, Lara-Medina F, et al. Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:385-394 10.1007/s10549-016-3811-2
• Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells Cite
  Kaczyńska A, Herman-Antosiewicz A. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells. Breast Cancer. Springer Science and Business Media LLC; 2016; 24:271-280 10.1007/s12282-016-0700-9
• In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases Cite
  Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, Luchini C, et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Archiv. Springer Science and Business Media LLC; 2016; 469:45-50 10.1007/s00428-016-1940-y
• Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer Cite
  Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, et al. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:145-156 10.1007/s10549-016-3790-3
• Prognostic impact of breast cancer subtypes in elderly patients Cite
  Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, et al. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:91-99 10.1007/s10549-016-3787-y
• Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01) Cite
  Agrawal S, Banswal L, Saha A, Arun I, Datta SS, Chatterjee S, et al. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01). Indian Journal of Surgical Oncology. Springer Science and Business Media LLC; 2016; 7:397-406 10.1007/s13193-016-0523-3
• Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab Cite
  Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, et al. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. American Medical Association (AMA); 2016; 2:1040 10.1001/jamaoncol.2016.0339
• Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer Cite
  Morrow M. Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:516 10.1001/jamaoncol.2015.4919
• Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer Cite
  Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2003-2009 10.1200/jco.2015.65.8716
• CD 8 + tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER 2‐positive ductal carcinoma in situ Cite
  Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, et al. CD 8 + tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER 2‐positive ductal carcinoma in situ. Cancer Medicine. Wiley; 2016; 5:1607-1618 10.1002/cam4.715
• Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population Cite
  Lim ST, Choi JE, Kim SJ, Kim HA, Kim JY, Park HK, et al. Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:473-483 10.1007/s10549-016-3771-6
• Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer Cite
  Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, et al. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2016; 142:1369-1376 10.1007/s00432-016-2146-z
• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Cite
  Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. Elsevier BV; 2016; 29:255-269 10.1016/j.ccell.2016.02.006
• Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer Cite
  Janni W, Schramm A, Friedl T, Schochter F, Huober J, Rack B, et al. Abstract P2-02-02: Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p2-02-02
• Abstract P1-16-06: Luteolin inhibits progestin-dependent VEGF induction, stem-cell like characteristics, and tumor progression of human breast cancer cells Cite
  Hyder S, Cook M, Besch-Williford C, Liang Y. Abstract P1-16-06: Luteolin inhibits progestin-dependent VEGF induction, stem-cell like characteristics, and tumor progression of human breast cancer cells. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p1-16-06
• Abstract P6-12-14: Comparative analysis of breast cancer phenotypes in African American, White American, and African patients- Correlation between African ancestry and triple negative breast cancer Cite
  Newman L, Jiagge E, Bensenhaver J, Chitale D, Kleer C, Merajver S, et al. Abstract P6-12-14: Comparative analysis of breast cancer phenotypes in African American, White American, and African patients- Correlation between African ancestry and triple negative breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p6-12-14
• The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study Cite
  Borgquist S, Zhou W, Jirström K, Amini R, Sollie T, Sørlie T, et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. Springer Science and Business Media LLC; 2015; 15 10.1186/s12885-015-1479-3
• Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens Cite
  Evans DG, Lalloo F, Howell S, Verhoef S, Woodward ER, Howell A. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:597-601 10.1007/s10549-016-3697-z
• Healthy dietary patterns and risk of breast cancer by molecular subtype Cite
  Hirko KA, Willett WC, Hankinson SE, Rosner BA, Beck AH, Tamimi RM, et al. Healthy dietary patterns and risk of breast cancer by molecular subtype. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:579-588 10.1007/s10549-016-3706-2
• Clinical predictors of long-term survival in HER2-positive metastatic breast cancer Cite
  Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, et al. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:589-595 10.1007/s10549-016-3705-3
• Cardiomyopathy Associated With Targeted Therapy for Breast Cancer Cite
  Sivagnanam K, Rahman ZU, Paul T. Cardiomyopathy Associated With Targeted Therapy for Breast Cancer. The American Journal of the Medical Sciences. Elsevier BV; 2016; 351:194-199 10.1016/j.amjms.2015.11.014
• A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer Cite
  Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, et al. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2016; 46:407-414 10.1093/jjco/hyw013
• Antiproliferative and apoptosis induction of α-mangostin in T47D breast cancer cells Cite
  KRITSANAWONG S, INNAJAK S, IMOTO M, WATANAPOKASIN R. Antiproliferative and apoptosis induction of α-mangostin in T47D breast cancer cells. International Journal of Oncology. Spandidos Publications; 2016; 48:2155-2165 10.3892/ijo.2016.3399
• Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab Cite
  Cañas A, López-Sánchez LM, Peñarando J, Valverde A, Conde F, Hernández V, et al. Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV; 2016; 1862:601-610 10.1016/j.bbadis.2016.02.005
• Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database Cite
  Tseng YD, Uno H, Hughes ME, Niland JC, Wong Y, Theriault R, et al. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2015; 93:622-630 10.1016/j.ijrobp.2015.07.006
• Palbociclib: A breakthrough in breast carcinoma in women Cite
  Gupta AK, Sharma S, Dahiya N, Brashier D. Palbociclib: A breakthrough in breast carcinoma in women. Medical Journal Armed Forces India. Elsevier BV; 2016; 72:S37-S42 10.1016/j.mjafi.2015.11.002
• Differential Effects of Organic and Inorganic Mercury on Phenotypically Variant Breast Cancer Cell Lines Cite
  R Wallace D. Differential Effects of Organic and Inorganic Mercury on Phenotypically Variant Breast Cancer Cell Lines. Journal of Clinical Toxicology. OMICS Publishing Group; 2016; 05 10.4172/2161-0495.1000273
• Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab Cite
  Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, et al. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. The Breast. Elsevier BV; 2016; 25:22-26 10.1016/j.breast.2015.11.006
• Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer Cite
  Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:29 10.1001/jamaoncol.2015.3709
• Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors Cite
  Nakamura R, Yamamoto N, Shiina N, Miyaki T, Ikebe D, Itami M, et al. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors. The Breast. Elsevier BV; 2016; 26:141-147 10.1016/j.breast.2015.10.009
• Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis Cite
  Vinod BS, Nair HH, Vijayakurup V, Shabna A, Shah S, Krishna A, et al. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis. Cell Death Discovery. Springer Science and Business Media LLC; 2015; 1 10.1038/cddiscovery.2015.61
• Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy Cite
  Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine. Springer Science and Business Media LLC; 2015; 13 10.1186/s12916-015-0540-z
• Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cells Cite
  KANG DY, DARVIN P, YOO YB, JOUNG YH, SP N, BYUN HJ, et al. Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cells. International Journal of Oncology. Spandidos Publications; 2015; 48:836-842 10.3892/ijo.2015.3277
• Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry Cite
  Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology. Elsevier BV; 2016; 27:480-487 10.1093/annonc/mdv611
• Long-term survival and stage I breast cancer subtypes Cite
  Cheng SH, Yu B, Horng C, Tsai SY, Chen C, Chu N, et al. Long-term survival and stage I breast cancer subtypes. Journal of Cancer Research and Practice. Medknow; 2016; 3:1-8 10.1016/j.jcrpr.2015.10.005
• Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474) Cite
  Mason JK, Fu M, Chen J, Thompson LU. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). The Journal of Nutritional Biochemistry. Elsevier BV; 2015; 26:16-23 10.1016/j.jnutbio.2014.08.001
• Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base Cite
  Killelea BK, Yang VQ, Wang S, Hayse B, Mougalian S, Horowitz NR, et al. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:4267-4276 10.1200/jco.2015.63.7801
• α-Linolenic Acid Reduces Growth of Both Triple Negative and Luminal Breast Cancer Cells in High and Low Estrogen Environments Cite
  Wiggins AKA, Kharotia S, Mason JK, Thompson LU. α-Linolenic Acid Reduces Growth of Both Triple Negative and Luminal Breast Cancer Cells in High and Low Estrogen Environments. Nutrition and Cancer. Informa UK Limited; 2015; 67:1001-1009 10.1080/01635581.2015.1053496
• Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells Cite
  Ravacci GR, Brentani MM, Tortelli TC, Torrinhas RSMM, Santos JR, Logullo AF, et al. Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells. BioMed Research International. Hindawi Limited; 2015; 2015:1-13 10.1155/2015/838652
• Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells Cite
  Pan S, Yuan C, Tagmount A, Rudel RA, Ackerman JM, Yaswen P, et al. Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells. Environmental Health Perspectives. Environmental Health Perspectives; 2016; 124:563-569 10.1289/ehp.1409200
• Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation Cite
  MAWATARI T, NINOMIYA I, INOKUCHI M, HARADA S, HAYASHI H, OYAMA K, et al. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. International Journal of Oncology. Spandidos Publications; 2015; 47:2073-2081 10.3892/ijo.2015.3213
• Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells Cite
  Seo H, Jo J, Ku J, Choi H, Choi Y, Woo J, et al. Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells. Bioscience Reports. Portland Press Ltd.; 2015; 35 10.1042/bsr20150165
• The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study Cite
  Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, et al. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv301 10.1093/jnci/djv301
• Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab Cite
  Sharieh EA, Awidi AS, Ahram M, Zihlif MA. Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab. Gene. Elsevier BV; 2016; 575:415-420 10.1016/j.gene.2015.09.019
• Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals Cite
  Zhang X, Wang H, Liu N, Ge L. Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals. Archives of Biochemistry and Biophysics. Elsevier BV; 2015; 585:10-16 10.1016/j.abb.2015.09.006
• The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer Cite
  Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, et al. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0136731 10.1371/journal.pone.0136731
• Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ Cite
  Davis JE, Nemesure B, Mehmood S, Nayi V, Burke S, Brzostek SR, et al. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. Applied Immunohistochemistry & Molecular Morphology. Ovid Technologies (Wolters Kluwer Health); 2016; 24:20-25 10.1097/pai.0000000000000223
• Abstract 5556: Enhancing response of Ganoderma lucidum (Reishi) and lapatinib in HER2+ inflammatory breast cancer cells Cite
  Feliz-Mosquea Y, Suarez-Arroyo I, Loperena Y, Cubano LA, Martinez-Montemayor MM. Abstract 5556: Enhancing response of Ganoderma lucidum (Reishi) and lapatinib in HER2+ inflammatory breast cancer cells. Cancer Chemistry. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-5556
• Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis Cite
  Cook MT, Liang Y, Goyette S, Mafuvadze B, Besch-Williford C, Hyder S. Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis. Tumor Biology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-4159
• Abstract 3735: Dietary sugar induces tumorigenesis in mammary gland partially through 12 lipoxygenase pathway Cite
  Jiang Y, Pan Y, Rhea PR, Tan L, Gagea-Iurascu M, Cohen L, et al. Abstract 3735: Dietary sugar induces tumorigenesis in mammary gland partially through 12 lipoxygenase pathway. Prevention Research. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-3735
• Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer Cite
  Shao Y, Sun X, He Y, Liu C, Liu H. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0133830 10.1371/journal.pone.0133830
• Mango polyphenolics suppressed tumor growth in breast cancer xenografts in mice: role of the PI3K/AKT pathway and associated microRNAs Cite
  Banerjee N, Kim H, Krenek K, Talcott ST, Mertens-Talcott SU. Mango polyphenolics suppressed tumor growth in breast cancer xenografts in mice: role of the PI3K/AKT pathway and associated microRNAs. Nutrition Research. Elsevier BV; 2015; 35:744-751 10.1016/j.nutres.2015.06.002
• Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study Cite
  Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, et al. Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0126096 10.1371/journal.pone.0126096
• Abstract 913: Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer. Cite
  Burnett J, Korkaya H, Newman B, Conley S, Connarn J, Sun L, et al. Abstract 913: Natural product sulforaphane selectively inhibits breast cancer stem cells in basal and trastuzumab resistant Her2+ breast cancer.. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2013; 10.1158/1538-7445.am2013-913
• Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy Cite
  Strasser-Weippl K, Horick N, Smith IE, O’Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0568-1
• Clinical outcomes of prospectively treated 140 women with early stage breast cancer using accelerated partial breast irradiation with 3 dimensional computerized tomography based brachytherapy Cite
  Budrukkar A, Gurram L, Upreti RR, Munshi A, Jalali R, Badwe R, et al. Clinical outcomes of prospectively treated 140 women with early stage breast cancer using accelerated partial breast irradiation with 3 dimensional computerized tomography based brachytherapy. Radiotherapy and Oncology. Elsevier BV; 2015; 115:349-354 10.1016/j.radonc.2015.03.002
• Breast Cancer Subtypes Predispose the Site of Distant Metastases Cite
  Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, et al. Breast Cancer Subtypes Predispose the Site of Distant Metastases. American Journal of Clinical Pathology. Oxford University Press (OUP); 2015; 143:471-478 10.1309/ajcpyo5fsv3upexs
• Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence Cite
  Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, et al. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2015; 41:548-552 10.1016/j.ejso.2015.01.030
• The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate Cite
  Kim S, Singh SV. The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 149:681-692 10.1007/s10549-015-3279-5
• Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment? Cite
  Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, et al. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?. Clinical Breast Cancer. Elsevier BV; 2015; 15:277-284 10.1016/j.clbc.2014.12.012
• Pattern of metastasis and outcome in patients with breast cancer Cite
  Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2015; 32:125-133 10.1007/s10585-015-9697-2
• Risk of subsequentin situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinomain situ Cite
  Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, et al. Risk of subsequentin situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinomain situ. Annals of Oncology. Elsevier BV; 2015; 26:682-687 10.1093/annonc/mdv013
• Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway Cite
  Khan A, Aljarbou AN, Aldebasi YH, Faisal SM, Khan MA. Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway. Cancer Epidemiology. Elsevier BV; 2014; 38:765-772 10.1016/j.canep.2014.09.006
• Abstract 3219: Synergistic effect between Ganoderma lucidum (Reishi) and lapatinib in HER2+ inflammatory breast cancer cells Cite
  Feliz-Mosquea Y, Suárez-Arroyo I, Cubano LA, Martínez-Montemayor MM. Abstract 3219: Synergistic effect between Ganoderma lucidum (Reishi) and lapatinib in HER2+ inflammatory breast cancer cells. Cancer Chemistry. American Association for Cancer Research; 2014; 10.1158/1538-7445.am2014-3219
• Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells Cite
  KIM S, KIL WH, LEE J, OH S, HAN J, JEON M, et al. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. Oncology Reports. Spandidos Publications; 2014; 32:2666-2672 10.3892/or.2014.3514
• Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Cite
  Sheridan W, Scott T, Caroline S, Yvonne Z, Vanessa B, David V, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 147:617-629 10.1007/s10549-014-3125-1
• The prognostic value of lymph node status among breast cancer subtypes Cite
  Liao G, Chou Y, Hsu H, Dai M, Yu J. The prognostic value of lymph node status among breast cancer subtypes. The American Journal of Surgery. Elsevier BV; 2015; 209:717-724 10.1016/j.amjsurg.2014.05.029
• Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo Cite
  LIU W, XU J, LIU Y, YU X, TANG X, WANG Z, et al. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Molecular Medicine Reports. Spandidos Publications; 2014; 10:1921-1926 10.3892/mmr.2014.2414
• Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation Cite
  Tuccari G, Ieni A, Barresi V, Caltabiano R, Zeppa P, Del Sordo R, et al. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. OncoTargets and Therapy. Informa UK Limited; 2014;:1267 10.2147/ott.s65294
• Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake Cite
  Seibold P, Vrieling A, Heinz J, Obi N, Sinn H, Flesch-Janys D, et al. Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. Cancer Epidemiology. Elsevier BV; 2014; 38:419-426 10.1016/j.canep.2014.05.006
• Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer Cite
  Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. Wiley; 2014; 120:2657-2664 10.1002/cncr.28710
• Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice Cite
  Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A, et al. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice. The Breast. Elsevier BV; 2014; 23:573-578 10.1016/j.breast.2014.05.022
• Screening to Identify Commonly Used Chinese Herbs That AffectERBB2andESR1Gene Expression Using the Human Breast Cancer MCF-7 Cell Line Cite
  Chiu J, Chang C, Wu J, Liu H, Wen C, Hsu C, et al. Screening to Identify Commonly Used Chinese Herbs That AffectERBB2andESR1Gene Expression Using the Human Breast Cancer MCF-7 Cell Line. Evidence-Based Complementary and Alternative Medicine. Hindawi Limited; 2014; 2014:1-11 10.1155/2014/965486
• Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Cite
  Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet Oncology. Elsevier BV; 2014; 15:640-647 10.1016/s1470-2045(14)70080-4
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Cite
  André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. Elsevier BV; 2014; 15:580-591 10.1016/s1470-2045(14)70138-x
• Wasabi-Derived 6-(Methylsulfinyl)Hexyl Isothiocyanate Induces Apoptosis in Human Breast Cancer by Possible Involvement of the NF-κB Pathways Cite
  Fuke Y, Hishinuma M, Namikawa M, Oishi Y, Matsuzaki T. Wasabi-Derived 6-(Methylsulfinyl)Hexyl Isothiocyanate Induces Apoptosis in Human Breast Cancer by Possible Involvement of the NF-κB Pathways. Nutrition and Cancer. Informa UK Limited; 2014; 66:879-887 10.1080/01635581.2014.916322
• Polyphenols of selected peach and plum genotypes reduce cell viability and inhibit proliferation of breast cancer cells while not affecting normal cells Cite
  Vizzotto M, Porter W, Byrne D, Cisneros-Zevallos L. Polyphenols of selected peach and plum genotypes reduce cell viability and inhibit proliferation of breast cancer cells while not affecting normal cells. Food Chemistry. Elsevier BV; 2014; 164:363-370 10.1016/j.foodchem.2014.05.060
• US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status Cite
  Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106 10.1093/jnci/dju055
• Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
  Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2014; 17:40 10.4048/jbc.2014.17.1.40
• Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Cite
  Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of Oncology. Elsevier BV; 2014; 25:1128-1136 10.1093/annonc/mdu118
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Cite
  Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. Elsevier BV; 2014; 384:164-172 10.1016/s0140-6736(13)62422-8
• Long-term exposure to dietary sources of genistein induces estrogen-independence in the human breast cancer (MCF-7) xenograft model Cite
  Andrade JE, Ju YH, Baker C, Doerge DR, Helferich WG. Long-term exposure to dietary sources of genistein induces estrogen-independence in the human breast cancer (MCF-7) xenograft model. Molecular Nutrition & Food Research. Wiley; 2014; 59:413-423 10.1002/mnfr.201300780
• Polyphenolics from peach (Prunus persica var. Rich Lady) inhibit tumor growth and metastasis of MDA-MB-435 breast cancer cells in vivo Cite
  Noratto G, Porter W, Byrne D, Cisneros-Zevallos L. Polyphenolics from peach (Prunus persica var. Rich Lady) inhibit tumor growth and metastasis of MDA-MB-435 breast cancer cells in vivo. The Journal of Nutritional Biochemistry. Elsevier BV; 2014; 25:796-800 10.1016/j.jnutbio.2014.03.001
• Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer Cite
  Gorshein E, Klein P, Boolbol SK, Shao T. Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2014; 14:309-314 10.1016/j.clbc.2014.02.007
• Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer Cite
  Gagliato DdM, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, et al. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014; 32:735-744 10.1200/jco.2013.49.7693
• Delphinidin inhibits cell proliferation and induces apoptosis in MDA-MB-231 human breast cancer cell lines Cite
  Seo EY. Delphinidin inhibits cell proliferation and induces apoptosis in MDA-MB-231 human breast cancer cell lines. Journal of Nutrition and Health. The Korean Nutrition Society; 2013; 46:503 10.4163/jnh.2013.46.6.503
• LDL-cholesterol signaling induces breast cancer proliferation and invasion Cite
  Rodrigues dos Santos C, Domingues G, Matias I, Matos J, Fonseca I, de Almeida J, et al. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids in Health and Disease. Springer Science and Business Media LLC; 2014; 13:16 10.1186/1476-511x-13-16
• Folic Acid Supplementation Promotes Mammary Tumor Progression in a Rat Model Cite
  Deghan Manshadi S, Ishiguro L, Sohn K, Medline A, Renlund R, Croxford R, et al. Folic Acid Supplementation Promotes Mammary Tumor Progression in a Rat Model. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e84635 10.1371/journal.pone.0084635
• Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials Cite
  Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, et al. Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. Annals of Oncology. Elsevier BV; 2014; 25:618-623 10.1093/annonc/mdt528
• Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes Cite
  Masuda H, Brewer T, Liu D, Iwamoto T, Shen Y, Hsu L, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Annals of Oncology. Elsevier BV; 2014; 25:384-391 10.1093/annonc/mdt525
• Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice Cite
  Lakritz JR, Poutahidis T, Levkovich T, Varian BJ, Ibrahim YM, Chatzigiagkos A, et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. International Journal of Cancer. Wiley; 2014; 135:529-540 10.1002/ijc.28702
• Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice Cite
  Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z, Terry C, et al. Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer. Springer Science and Business Media LLC; 2013; 13 10.1186/1471-2407-13-418
• Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients Cite
  Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, et al. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. European Journal of Cancer. Elsevier BV; 2013; 49:3588-3597 10.1016/j.ejca.2013.07.016
• Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? Cite
  Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, et al. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 87:344-348 10.1016/j.ijrobp.2013.05.052
• Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model Cite
  Gupta P, Adkins C, Lockman P, Srivastava SK. Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e67278 10.1371/journal.pone.0067278
• Co-treatment with Quercetin and 1,2,3,4,6-Penta-O-galloyl-β-d-glucose Causes Cell Cycle Arrest and Apoptosis in Human Breast Cancer MDA-MB-231 and AU565 Cells Cite
  Huang C, Lee S, Lin C, Tu T, Chen LH, Chen YJ, et al. Co-treatment with Quercetin and 1,2,3,4,6-Penta-O-galloyl-β-d-glucose Causes Cell Cycle Arrest and Apoptosis in Human Breast Cancer MDA-MB-231 and AU565 Cells. Journal of Agricultural and Food Chemistry. American Chemical Society (ACS); 2013; 61:6430-6445 10.1021/jf305253m
• Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18–40 Years at Diagnosis: The POSH Study Cite
  Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, et al. Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18–40 Years at Diagnosis: The POSH Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:978-988 10.1093/jnci/djt134
• Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis Cite
  Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, et al. Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis. The Oncologist. Wiley; 2013; 18:667-674 10.1634/theoncologist.2012-0350
• Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells Cite
  Do MT, Kim HG, Choi JH, Khanal T, Park BH, Tran TP, et al. Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. Food Chemistry. Elsevier BV; 2013; 141:2591-2599 10.1016/j.foodchem.2013.04.125
• Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Cite
  Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. Wiley; 2013; 119:2447-2454 10.1002/cncr.28051
• Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer Cite
  Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, et al. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocrine-Related Cancer. Bioscientifica; 2013; 20:391-401 10.1530/erc-12-0333
• Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer Cite
  Kim M, Allen P, Gonzalez-Angulo A, Woodward W, Meric-Bernstam F, Buzdar A, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology. Elsevier BV; 2013; 24:1999-2004 10.1093/annonc/mdt131
• Abstract 3691: Fish oil increases immune cell infiltration of tumors and reduces the incidence of mammary carcinogenesis in Her2neu mice. Cite
  Turbitt WJ, Collins SD, Xu H, Washington S, Aliaga C, El-Bayoumy K, et al. Abstract 3691: Fish oil increases immune cell infiltration of tumors and reduces the incidence of mammary carcinogenesis in Her2neu mice.. Prevention Research. American Association for Cancer Research; 2013; 10.1158/1538-7445.am2013-3691
• Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer Cite
  Krishnamurthy S, Bischoff F, Ann Mayer J, Wong K, Pham T, Kuerer H, et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Medicine. Wiley; 2013; 2:226-233 10.1002/cam4.70
• Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab Cite
  Olson E, Abdel-Rasoul M, Maly J, Wu C, Lin N, Shapiro C. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Annals of Oncology. Elsevier BV; 2013; 24:1526-1533 10.1093/annonc/mdt036
• Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer Cite
  Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clinical Chemistry and Laboratory Medicine. Walter de Gruyter GmbH; 2013; 51 10.1515/cclm-2012-0488
• Sulforaphane inhibits growth of phenotypically different breast cancer cells Cite
  Pawlik A, Wiczk A, Kaczyńska A, Antosiewicz J, Herman-Antosiewicz A. Sulforaphane inhibits growth of phenotypically different breast cancer cells. European Journal of Nutrition. Springer Science and Business Media LLC; 2013; 52:1949-1958 10.1007/s00394-013-0499-5
• 3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells Cite
  Ahmad A, Ali S, Ahmed A, Ali AS, Raz A, Sakr WA, et al. 3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e54657 10.1371/journal.pone.0054657
• Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction Cite
  Kneubil M, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, et al. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2013; 39:260-265 10.1016/j.ejso.2012.12.004
• Direct regulation of caspase-3 by the transcription factor AP-2α is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells Cite
  YAN F, HE Q, HU X, LI W, WEI K, LI L, et al. Direct regulation of caspase-3 by the transcription factor AP-2α is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells. Molecular Medicine Reports. Spandidos Publications; 2013; 7:909-914 10.3892/mmr.2013.1257
• Chronic Morphine Treatment Attenuates Cell Growth of Human BT474 Breast Cancer Cells by Rearrangement of the ErbB Signalling Network Cite
  Weingaertner IR, Koutnik S, Ammer H. Chronic Morphine Treatment Attenuates Cell Growth of Human BT474 Breast Cancer Cells by Rearrangement of the ErbB Signalling Network. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e53510 10.1371/journal.pone.0053510
• Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice Cite
  Castillo-Pichardo L, Cubano LA, Dharmawardhane S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complementary and Alternative Medicine. Springer Science and Business Media LLC; 2013; 13 10.1186/1472-6882-13-6
• Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines Cite
  Woode DR, Aiyer HS, Sie N, Zwart AL, Li L, Seeram NP, et al. Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines. International Journal of Breast Cancer. Hindawi Limited; 2012; 2012:1-11 10.1155/2012/147828
• Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact Cite
  Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, et al. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact. Oncology. S. Karger AG; 2013; 84:150-157 10.1159/000345795
• Abstract 585: Eicosapentaenoic acid increases mammary tumor inhibition of intermittent calorie restriction and regulates adipokines Cite
  Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP, Grossmann ME. Abstract 585: Eicosapentaenoic acid increases mammary tumor inhibition of intermittent calorie restriction and regulates adipokines. Prevention Research. American Association for Cancer Research; 2012; 10.1158/1538-7445.am2012-585
• The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n -3 PUFAs Cite
  Yee LD, Agarwal D, Rosol TJ, Lehman A, Tian M, Hatton J, et al. The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n -3 PUFAs. Molecular Nutrition & Food Research. Wiley; 2012; 57:320-327 10.1002/mnfr.201200445
• A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease Cite
  Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram D. A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer. Springer Science and Business Media LLC; 2012; 12 10.1186/1471-2407-12-555
• Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer Cite
  Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2012; 60:2504-2512 10.1016/j.jacc.2012.07.068
• Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Cite
  Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:563-570 10.1007/s12282-012-0424-4
• Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome Cite
  Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, et al. Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. Clinical Breast Cancer. Elsevier BV; 2013; 13:31-39 10.1016/j.clbc.2012.09.002
• Inhibition of constitutive Akt (PKB) phosphorylation by docosahexaenoic acid in the human breast cancer cell line MDA-MB-453 Cite
  Sato SB, Park J, Kawamoto J, Sato S, Kurihara T. Inhibition of constitutive Akt (PKB) phosphorylation by docosahexaenoic acid in the human breast cancer cell line MDA-MB-453. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. Elsevier BV; 2013; 1831:306-313 10.1016/j.bbalip.2012.10.004
• Docosahexanoic Acid Improves Chemotherapy Efficacy by Inducing CD95 Translocation to Lipid Rafts in ER− Breast Cancer Cells Cite
  Ewaschuk JB, Newell M, Field CJ. Docosahexanoic Acid Improves Chemotherapy Efficacy by Inducing CD95 Translocation to Lipid Rafts in ER− Breast Cancer Cells. Lipids. Wiley; 2012; 47:1019-1030 10.1007/s11745-012-3717-7
• Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse Cite
  Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua M, Pruneri G, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Annals of Oncology. Elsevier BV; 2013; 24:661-668 10.1093/annonc/mds430
• Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis Cite
  Dieci M, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. Annals of Oncology. Elsevier BV; 2013; 24:101-108 10.1093/annonc/mds248
• Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype Cite
  Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:153-160 10.1007/s10549-012-2243-x
• Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation Cite
  Banerjee N, Talcott S, Safe S, Mertens-Talcott SU. Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:21-34 10.1007/s10549-012-2224-0
• Pertuzumab: new hope for patients with HER2-positive breast cancer Cite
  Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini K, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology. Elsevier BV; 2013; 24:273-282 10.1093/annonc/mds328
• Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer Cite
  Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 135:849-855 10.1007/s10549-012-2183-5
• High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation Cite
  Chang N, Wu C, Chen D, Yeh C, Lin C. High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. The Journal of Nutritional Biochemistry. Elsevier BV; 2013; 24:274-281 10.1016/j.jnutbio.2012.06.005
• Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study Cite
  Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. The Breast. Elsevier BV; 2013; 22:301-308 10.1016/j.breast.2012.07.012
• Biomarkers of Phenethyl Isothiocyanate-Mediated Mammary Cancer Chemoprevention in a Clinically Relevant Mouse Model Cite
  Singh SV, Kim S, Sehrawat A, Arlotti JA, Hahm E, Sakao K, et al. Biomarkers of Phenethyl Isothiocyanate-Mediated Mammary Cancer Chemoprevention in a Clinically Relevant Mouse Model. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:1228-1239 10.1093/jnci/djs321
• Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology) Cite
  Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumussoy O, Yildiz R, et al. Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology). Oncology. S. Karger AG; 2012; 83:141-150 10.1159/000338782
• Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer Cite
  Wang Q, Li S, Wang H, Xiao Y, Sahin O, Brady SW, et al. Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2012; 72:4417-4428 10.1158/0008-5472.can-12-1339-t
• HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis Cite
  Hartman ZC, Yang X, Glass O, Lei G, Osada T, Dave SS, et al. HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis. Cancer Research. American Association for Cancer Research (AACR); 2011; 71:4380-4391 10.1158/0008-5472.can-11-0308
• Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population Cite
  Korkaya H, Kim G, Davis A, Malik F, Henry N, Ithimakin S, et al. Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population. Molecular Cell. Elsevier BV; 2012; 47:570-584 10.1016/j.molcel.2012.06.014
• Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin Cite
  Sun S, Huang H, Huang C, Lin J. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. European Journal of Pharmacology. Elsevier BV; 2012; 690:22-30 10.1016/j.ejphar.2012.05.036
• Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/neu transgenic mice Cite
  Rossini A, Zanobbio L, Sfondrini L, Cavalleri A, Secreto G, Morelli D, et al. Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/neu transgenic mice. Journal of Cellular Physiology. Wiley; 2012; 228:242-249 10.1002/jcp.24130
• Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors Cite
  Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM. Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors. Hormones and Cancer. Springer Science and Business Media LLC; 2012; 3:160-171 10.1007/s12672-012-0114-x
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Cite
  Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
• Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network Cite
  Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. Wiley; 2012; 118:5463-5472 10.1002/cncr.27581
• Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials Cite
  Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews. Elsevier BV; 2013; 39:44-50 10.1016/j.ctrv.2012.03.009
• Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010 Cite
  García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, et al. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. The Breast. Elsevier BV; 2012; 21:366-373 10.1016/j.breast.2012.03.004
• Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence Cite
  Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, et al. Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence. Clinical Oncology. Elsevier BV; 2012; 24:183-189 10.1016/j.clon.2011.09.008
• Invasive lobular breast cancer: subtypes and outcome Cite
  Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 133:713-723 10.1007/s10549-012-2002-z
• Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells Cite
  Navarro-Tito N, Robledo T, Salazar EP. Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells. Experimental Cell Research. Elsevier BV; 2008; 314:3340-3355 10.1016/j.yexcr.2008.08.018
• HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ Cite
  Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. British Journal of Cancer. Springer Science and Business Media LLC; 2012; 106:1160-1165 10.1038/bjc.2012.41
• Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3 Cite
  Menendez J. Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. International Journal of Oncology. Spandidos Publications; 2011; 10.3892/ijo.2011.993
• Radiation Effects on Development of HER2-Positive Breast Carcinomas Cite
  Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, et al. Radiation Effects on Development of HER2-Positive Breast Carcinomas. Clinical Cancer Research. American Association for Cancer Research (AACR); 2007; 13:46-51 10.1158/1078-0432.ccr-06-1490
• Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial Cite
  Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:406-414 10.1093/jnci/djr543
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Cite
  Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Elsevier BV; 2012; 379:633-640 10.1016/s0140-6736(11)61847-3
• Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation Cite
  Yang X, Yang S, McKimmey C, Liu B, Edgerton SM, Bales W, et al. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis. Oxford University Press (OUP); 2010; 31:695-702 10.1093/carcin/bgq007
• Additive effects of trastuzumab and genistein on human breast cancer cells Cite
  Lattrich C, Lubig J, Springwald A, Goerse R, Ortmann O, Treeck O. Additive effects of trastuzumab and genistein on human breast cancer cells. Anti-Cancer Drugs. Ovid Technologies (Wolters Kluwer Health); 2011; 22:253-261 10.1097/cad.0b013e3283427bb5
• Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells Cite
  Sakla MS, Shenouda NS, Ansell PJ, MacDonald RS, Lubahn DB. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine. Springer Science and Business Media LLC; 2007; 32:69-78 10.1007/s12020-007-9006-1
• Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells Cite
  Mai Z, Blackburn GL, Zhou J. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Molecular Carcinogenesis. Wiley; 2007; 46:534-542 10.1002/mc.20300
• Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ Cite
  Halasz LM, Sreedhara M, Chen Y, Bellon JR, Punglia RS, Wong JS, et al. Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 82:e581-e586 10.1016/j.ijrobp.2011.08.015
• Differential Influence of Dietary Soy Intake on the Risk of Breast Cancer Recurrence Related to HER2 Status Cite
  Woo HD, Park K, Ro J, Kim J. Differential Influence of Dietary Soy Intake on the Risk of Breast Cancer Recurrence Related to HER2 Status. Nutrition and Cancer. Informa UK Limited; 2012; 64:198-205 10.1080/01635581.2012.635261
• Urinary strontium and the risk of breast cancer: A case-control study in Guangzhou, China Cite
  Chen L, Tang L, He J, Su Y, Cen Y, Yu D, et al. Urinary strontium and the risk of breast cancer: A case-control study in Guangzhou, China. Environmental Research. Elsevier BV; 2012; 112:212-217 10.1016/j.envres.2011.11.005
• Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro Cite
  Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. Informa UK Limited; 2009; 8:909-915 10.4161/cc.8.6.7933
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) Cite
  Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®). Clinical and Translational Oncology. Springer Science and Business Media LLC; 2009; 11:455-459 10.1007/s12094-009-0384-0
• Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer Cite
  Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer. Journal of Cardiac Failure. Elsevier BV; 2012; 18:113-119 10.1016/j.cardfail.2011.10.015
• Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Cite
  Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 133:831-841 10.1007/s10549-011-1891-6
• Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer Cite
  Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:587-592 10.1200/jco.2010.33.5232
• Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer Cite
  He X, Esteva F, Ensor J, Hortobagyi G, Lee M, Yeung SJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:1771-1780 10.1093/annonc/mdr534
• Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2 /M arrest and apoptosis Cite
  Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, et al. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2 /M arrest and apoptosis. Molecular Carcinogenesis. Wiley; 2011; 52:134-143 10.1002/mc.21839
• Chronic Oral Exposure to Bisphenol A Results in a Nonmonotonic Dose Response in Mammary Carcinogenesis and Metastasis in MMTV-erbB2 Mice Cite
  Jenkins S, Wang J, Eltoum I, Desmond R, Lamartiniere CA. Chronic Oral Exposure to Bisphenol A Results in a Nonmonotonic Dose Response in Mammary Carcinogenesis and Metastasis in MMTV-erbB2 Mice. Environmental Health Perspectives. Environmental Health Perspectives; 2011; 119:1604-1609 10.1289/ehp.1103850
• Alcohol Promotes Mammary Tumor Development via the Estrogen Pathway in Estrogen Receptor Alpha-Negative HER2/neu Mice Cite
  Wong AW, Dunlap SM, Holcomb VB, Nunez NP. Alcohol Promotes Mammary Tumor Development via the Estrogen Pathway in Estrogen Receptor Alpha-Negative HER2/neu Mice. Alcoholism: Clinical and Experimental Research. Wiley; 2011; 36:577-587 10.1111/j.1530-0277.2011.01654.x
• Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer Cite
  Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, et al. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2011; 29:1536-1542 10.1007/s12032-011-0082-y
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer Cite
  Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1273-1283 10.1056/nejmoa0910383
• Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cite
  Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. Wiley; 2011; 118:2385-2393 10.1002/cncr.26555
• Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression Cite
  Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2601-2608 10.1200/jco.2011.37.2482
• Breast cancer in very young women Cite
  Liukkonen S, Leidenius M, Saarto T, Sjöström-Mattson J. Breast cancer in very young women. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:1030-1037 10.1016/j.ejso.2011.08.133
• Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study Cite
  Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2011; 13 10.1186/bcr2944
• Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy Cite
  Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, et al. Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:3885-3891 10.1200/jco.2011.36.1105
• Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. Cite
  Takita C, Reis IM, Miao F, LaFave KE, Gunaseelan V, Hurley J, et al. Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:112-112 10.1200/jco.2011.29.27_suppl.112
• Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer Cite
  Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, et al. Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer. Oncology. S. Karger AG; 2011; 80:341-349 10.1159/000330203
• Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines Cite
  Ozbay T, Nahta R. Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2011; 5:BCBCR.S7156 10.4137/bcbcr.s7156
• Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics Cite
  Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1179-1189 10.1093/jnci/djr225
• Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer Cite
  Kim HJ, Lee YM, Ko BS, Lee JW, Yu JH, Son BH, et al. Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2010; 18:1830-1836 10.1245/s10434-010-1465-6
• Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions Cite
  Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. Informa UK Limited; 2011; 10:2959-2966 10.4161/cc.10.17.16359
• Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study Cite
  Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2011; 13 10.1186/bcr2891
• Biologic markers determine both the risk and the timing of recurrence in breast cancer Cite
  Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:607-616 10.1007/s10549-011-1564-5
• Blood Type, Hormone Receptor Status, HER2/neu Status, and Survival in Breast Cancer: A Retrospective Study Exploring Relationships in a Phenotypically Well-Defined Cohort Cite
  Klimant E, Glurich I, Mukesh B, Onitilo AA. Blood Type, Hormone Receptor Status, HER2/neu Status, and Survival in Breast Cancer: A Retrospective Study Exploring Relationships in a Phenotypically Well-Defined Cohort. Clinical Medicine & Research. Marshfield Clinic Research Foundation; 2011; 9:111-118 10.3121/cmr.2011.907
• Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status Cite
  Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, et al. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. International Journal of Cancer. Wiley; 2011; 130:1401-1410 10.1002/ijc.26157
• Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype Cite
  Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes & Control. Springer Science and Business Media LLC; 2011; 22:965-975 10.1007/s10552-011-9769-9
• Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas Cite
  Catasus L, Gallardo A, Llorente-Cortes V, Escuin D, Muñoz J, Tibau A, et al. Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas. Human Pathology. Elsevier BV; 2011; 42:1581-1588 10.1016/j.humpath.2011.01.011
• Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation Cite
  Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 128:899-906 10.1007/s10549-011-1495-1
• Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Cite
  Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 127:713-720 10.1007/s10549-011-1465-7
• Diets High in Corn Oil or Extra-Virgin Olive Oil Provided From Weaning Advance Sexual Maturation and Differentially Modify Susceptibility to Mammary Carcinogenesis in Female Rats Cite
  Moral R, Escrich R, Solanas M, Vela E, Costa I, de Villa MCR, et al. Diets High in Corn Oil or Extra-Virgin Olive Oil Provided From Weaning Advance Sexual Maturation and Differentially Modify Susceptibility to Mammary Carcinogenesis in Female Rats. Nutrition and Cancer. Informa UK Limited; 2011; 63:410-420 10.1080/01635581.2011.535956
• The Association between Prognostic Demographic and Tumor Characteristics of Breast Carcinomas with Serum 25-OH Vitamin D Levels Cite
  Peppone L, Rickles A, Huston A, Sprod L, Hicks D, Mustian K, et al. The Association between Prognostic Demographic and Tumor Characteristics of Breast Carcinomas with Serum 25-OH Vitamin D Levels. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:717.2-717 10.1158/1055-9965.epi-11-0089
• A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative Cite
  Thakkar JP, Mehta DG. A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative. The Oncologist. Wiley; 2011; 16:276-285 10.1634/theoncologist.2010-0302
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Cite
  Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology. Elsevier BV; 2011; 12:236-244 10.1016/s1470-2045(11)70033-x
• Risk of a Second Breast Cancer Associated with Hormone-Receptor and HER2/neu Status of the First Breast Cancer Cite
  Bessonova L, Taylor TH, Mehta RS, Zell JA, Anton-Culver H. Risk of a Second Breast Cancer Associated with Hormone-Receptor and HER2/neu Status of the First Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:389-396 10.1158/1055-9965.epi-10-1016
• A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone Cite
  Altenburg JD, Bieberich AA, Terry C, Harvey KA, VanHorn JF, Xu Z, et al. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer. Springer Science and Business Media LLC; 2011; 11 10.1186/1471-2407-11-149
• Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer Cite
  Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. Wiley; 2012; 118:5937-5946 10.1002/cncr.27527
• Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old Cite
  Karihtala P, Winqvist R, Bloigu R, Jukkola-Vuorinen A. Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old. The Breast. Elsevier BV; 2010; 19:456-461 10.1016/j.breast.2010.05.001
• Anticancer Activities of an Anthocyanin-Rich Extract From Black Rice Against Breast Cancer Cells In Vitro and In Vivo Cite
  Hui C, Bin Y, Xiaoping Y, Long Y, Chunye C, Mantian M, et al. Anticancer Activities of an Anthocyanin-Rich Extract From Black Rice Against Breast Cancer Cells In Vitro and In Vivo. Nutrition and Cancer. Informa UK Limited; 2010; 62:1128-1136 10.1080/01635581.2010.494821
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Cite
  von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:145-156 10.1007/s10549-010-1228-x
• Prognosis and Outcome of Small (≤1 cm), Node‐Negative Breast Cancer on the Basis of Hormonal and HER‐2 Status Cite
  Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, et al. Prognosis and Outcome of Small (≤1 cm), Node‐Negative Breast Cancer on the Basis of Hormonal and HER‐2 Status. The Oncologist. Wiley; 2010; 15:1043-1049 10.1634/theoncologist.2010-0036
• Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry Cite
  Telli ML, Chang ET, Kurian AW, Keegan THM, McClure LA, Lichtensztajn D, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 127:471-478 10.1007/s10549-010-1173-8
• Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk Cite
  Phipps AI, Buist DSM, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:671-678 10.1007/s10549-010-1148-9
• The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer Cite
  Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:187-194 10.1007/s10549-010-1135-1
• Impact of BMI on clinical outcome of HER2-positive breast cancer. Cite
  Parolin V, Fiorio E, Mercanti A, Riolfi M, Cetto GL, Surmacz E, et al. Impact of BMI on clinical outcome of HER2-positive breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1130-1130 10.1200/jco.2010.28.15_suppl.1130
• Individualized surveillance and follow-up based on breast cancer (BC) subtypes and risk of relapse in BC patients who received curative surgery. Cite
  Lee S, Park Y, Sun J, Seo J, Lee J, Nam S, et al. Individualized surveillance and follow-up based on breast cancer (BC) subtypes and risk of relapse in BC patients who received curative surgery.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11053-e11053 10.1200/jco.2010.28.15_suppl.e11053
• The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Cite
  Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:355-364 10.1007/s10549-010-0924-x
• Conservative surgery in patients with multifocal/multicentric breast cancer Cite
  Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 113:577-583 10.1007/s10549-008-9959-7
• Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer Cite
  Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 102:1391-1396 10.1038/sj.bjc.6605655
• Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study Cite
  O'Brien KM, Cole SR, Tse C, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. Clinical Cancer Research. American Association for Cancer Research (AACR); 2010; 16:6100-6110 10.1158/1078-0432.ccr-10-1533
• Abstract 5583: Innate immune profile of inflammatory breast cancer patients Cite
  Cohen EN, Gao H, Lee B, Andreopoulou E, Jackson SA, Parker CA, et al. Abstract 5583: Innate immune profile of inflammatory breast cancer patients. Clinical Research. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-5583
• Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study Cite
  Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study. Cancer Research. American Association for Cancer Research (AACR); 2010; 70:575-587 10.1158/0008-5472.can-09-3460
• Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. Cite
  Sparano J, Wang W, Stearns V, Martino S, Jones V, Perez E, et al. Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy.. General Session Abstracts. American Association for Cancer Research; 2009; 10.1158/0008-5472.sabcs-09-37
• 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells Cite
  Choi . 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncology Reports. Spandidos Publications; 2009; 22 10.3892/or_00000598
• Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Cite
  Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals of Oncology. Elsevier BV; 2010; 21:1254-1261 10.1093/annonc/mdp427
• Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway Cite
  Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, et al. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene. Springer Science and Business Media LLC; 2009; 29:285-296 10.1038/onc.2009.335
• Presenting Features of Breast Cancer Differ by Molecular Subtype Cite
  Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, et al. Presenting Features of Breast Cancer Differ by Molecular Subtype. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2009; 16:2705-2710 10.1245/s10434-009-0606-2
• Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements Cite
  Malewicz B. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis. Oxford University Press (OUP); 2006; 27:1739-1747 10.1093/carcin/bgl032
• ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies Cite
  Finn RS, Dering J, Ginther C, Press M, Forbes J, Mackey J, et al. ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2006; 24:514-514 10.1200/jco.2006.24.18_suppl.514
• 3,3′-Diindolylmethane and Paclitaxel Act Synergistically to Promote Apoptosis in HER2/Neu Human Breast Cancer Cells Cite
  McGuire K, Ngoubilly N, Neavyn M, Lanza-Jacoby S. 3,3′-Diindolylmethane and Paclitaxel Act Synergistically to Promote Apoptosis in HER2/Neu Human Breast Cancer Cells. Journal of Surgical Research. Elsevier BV; 2006; 132:208-213 10.1016/j.jss.2006.02.008
• Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells Cite
  Choi EJ, Kim G. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine. Elsevier BV; 2008; 15:683-690 10.1016/j.phymed.2008.04.006
• Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate Cite
  Chiesa G, Rigamonti E, Lovati MR, Disconzi E, Soldati S, Sacco MG, et al. Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate. Molecular Nutrition & Food Research. Wiley; 2008; 52:1121-1129 10.1002/mnfr.200700296
• Degradation of HER2/neuby apigenin induces apoptosis through cytochromecrelease and caspase-3 activation in HER2/neu-overexpressing breast cancer cells Cite
  Way T, Kao M, Lin J. Degradation of HER2/neuby apigenin induces apoptosis through cytochromecrelease and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Letters. Wiley; 2004; 579:145-152 10.1016/j.febslet.2004.11.061
• Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells Cite
  Chang CJ, Chiu JH, Tseng LM, Chang CH, Chien TM, Wu CW, et al. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. European Journal of Clinical Investigation. Wiley; 2006; 36:588-596 10.1111/j.1365-2362.2006.01676.x
• HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail» Cite
  Menéndez JA, Vázquez-Martín A, Ropero S, Colomer R, Lupu R, Trueta J. HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail». Clinical and Translational Oncology. Springer Science and Business Media LLC; 2006; 8:812-820 10.1007/s12094-006-0137-2
• Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells Cite
  Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells. BMC Cancer. Springer Science and Business Media LLC; 2007; 7 10.1186/1471-2407-7-80
• Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification Cite
  Menendez J, Vellon L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification. Annals of Oncology. Elsevier BV; 2005; 16:359-371 10.1093/annonc/mdi090
• Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells Cite
  Menendez JA, Lupu R, Colomer R. Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2005; 14:263-270 10.1097/00008469-200506000-00011
• Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neuin HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway Cite
  Way T, Kao M, Lin J. Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neuin HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway. Journal of Biological Chemistry. American Society for Biochemistry & Molecular Biology (ASBMB); 2003; 279:4479-4489 10.1074/jbc.m305529200
• Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2 Cite
  Menendez . Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. International Journal of Oncology. Spandidos Publications; 1992; 10.3892/ijo_00000127